Podcasts about Royal North Shore Hospital

In a special series dedicated to the Australian Clinical Entrepreneur Program (AUSCEP) we introduce you to some of the passionate health professionals taking part in this 12-month program to develop their innovative ideas into products and enterprises.Dr Yagiz Aksoy is a Resident Doctor at Royal North Shore Hospital in Sydney and co-founder and Director of EosGene Therapeutics, a startup developing a pioneering light-activated gene therapy for diabetic retinopathy and macular degeneration using proprietary drug delivery technology – removing the need for painful eye injections.Yagiz explains how taking part in AUSCEP helped him shift from being a clinician researcher to becoming a translational founder, giving him the language and tools to navigate startup strategy. And it gifted him a community of clinicians trying to solve real problems in different ways.The program's third cohort has been delivered in NSW and Victoria, in partnership with MTPConnect and Australian Society for Medical Entrepreneurship and Innovation (ASME) and supported by LaunchVic and NSW Agency for Clinical Innovation (ACI). The next 2025/26 cohort is open for Victorian applications until 20 June 2025 – apply at auscep.au.This episode is hosted by MTPConnect's Caroline Duell and Elizabeth Stares.

In this piece we discuss prevention of intraoperative hypothermia with Holly Tonkin, a trainee anaesthetist from Australia. Holly describes her study, in which she measured the prevalence of hypothermia using routine forced air warming and then the prevalence using the 3M™ Bair Hugger™ Universal Warming Gown. Significant reductions in hypothermia were observed. Holly's study was supported by Solventum. We then discussed the value of trainee research. Presented by Andy Cumpstey and Kate Leslie on location at the Annual Scientific Meeting of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine in Cairns, Australia, with their guest, Dr Holly Tonkin, Manning Base Hospital and Royal North Shore Hospital, New South Wales, Australia.

We never thought we'd see the day that a doctor joined us on the pod, and to be honest, we couldn't be more grateful to have Dr. Kieran McCaffrey with us. Having trained at Royal North Shore Hospital, Dr. McCaffrey is an obstetrician and gynaecologist. Fun fact: he is one of 11 children (10 boys, 1 girl). Yes, you heard that correctly. His dad is an OB, and two of his brothers are also doctors. Genius genes!We asked Dr. McCaffrey every question under the sun about pregnancy and birth, including (but not limited to): when to take your undies off (vitally important), how to limit interventions, managing mental health and migraines during pregnancy, forceps delivery, low-lying placenta, an en caul baby (yep, that's French for "under the veil" for you non-bilingual folks), what a teratoma is, and everything in between.We hope you enjoy!Kolide Advice || Dr McCaffrey || Baby Bible + Hydra MamaElla || Watch VigilSteph || Drink / Eat || Lox in Box Matcha + Cookies Hosted on Acast. See acast.com/privacy for more information.

In this episode, we discuss the clinical and diagnostic markers when identifying a rare sub type of NSCLC, large-cell neuroendocrine carcinomas (LC-NEC), and provide insights into the management of these patients and future treatment developments. Associate Professor Rachel Wong, Deputy Director Oncology Eastern Health and Medical Oncologist at Epworth East in Melbourne is joined by Dr Patrick Hosking, Senior Histopathologist at Eastern Health Pathology; Dr Mal Itchins, Thoracic Medical Oncologist at Royal North Shore Hospital and Chris O'Brien LifeHouse in Sydney and Dr Sagun Parakh, Medical Oncologist at the Austin Hospital, Lung Cancer Lead. https://www.omico.com.au/our-programs/cancer-screening-program-casp/

In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a discussion about the management of relapsed SCLC, which remains a very challenging cancer to treat, despite recent progress. Guest: Dr. Malinda Itchins is a Medical Oncologist at Royal North Shore Hospital, Visiting Medical Officer for Thoracic Cancers at Chris O'Brien Lifehouse, and Faculty at the University of Sydney. She is the Board Director and Lung Cancer Chair for the Clinical Oncology Society of Australia (COSA) and the Scientific Committee Advanced NSCLC Group Co-Chair for the Thoracic Oncology Group of Australasia (TOGA). Guest: Dr. Jacob Sands is an Assistant Professor at Harvard Medical School and Thoracic Medical Oncologist at the Lowe Center for Thoracic Oncology at the Dana Farber Cancer Institute, where he leads the Clinical Research Program in SCLC. Jacob is also Co-founder and President of the Rescue Lung Society, a 501(c)3 society focused on advancing lung cancer screening.

This is the first in the four-part series on anatomical trauma with some of the world's leading experts on specialist pre-hospital care. In today's episode, we delve into the complexities of assessing and treating thoracic injuries in pre-hospital care. We'll cover a range of topics, including pneumothorax, haemothorax, and flail chest. Our discussion will span the primary and secondary survey, airway management considerations, and the efficacy and evolution of modern interventions such as needle decompression. To bring these concepts to life, we'll examine real-life cases that highlight the challenges faced by healthcare professionals in the field. Joining me is Geoff Healey, a distinguished Prehospital and Retrieval Physician with Sydney HEMS. Geoff also serves as a Consultant Anaesthetist at Royal North Shore Hospital in Sydney and the Deputy Medical Manager for Sydney HEMS. With extensive experience in Australia's and the UK's Prehospital and Retrieval Systems, Geoff brings invaluable insights into our conversation. Additionally, he is an active member of the NSW Taskforce Urban Search and Rescue Team and has been deployed on numerous humanitarian missions worldwide. We unpack the intricacies of thoracic trauma management in pre-hospital settings, guided by Geoff's expert knowledge and frontline experiences.

With 18 years' experience working across health, science, education and research projects at BVN, Conor Larkins will head up HDR's health sector and work with directors to elevate the practice's design rigour and deliver human-centred facilities.  Larkins has worked across many of Australia's most significant health precincts, including Prince of Wales Acute Services Building, the Lang Walker AO Medical Research Building, Nepean Hospital Redevelopment, Royal North Shore Hospital, and Northside Hospital in Canberra. In this exclusive interview, we talk about how designers prioritize resilience in healthcare design, and how to enable facilities to readily respond to disruptions, big and small, and adapt as needs evolve. This Podcast was brought to you by Siniat, proud sponsors of our 2024 Aged & Healthcare series.

Do we need to evolve the bar on evidence required for drug reimbursement? The gold standard endpoint for assessing the benefit of anti-cancer drugs has been overall survival (OS) however, more recently, there has been a trend toward using surrogate clinical trial endpoints such as progression free survival (PFS) and event-free survival (EFS). As treatments improve and patients are living longer, using OS as a primary endpoint can mean a longer time until a result is obtained. In this podcast, Dr Rebecca Tay, Medical Oncologist at Royal Hobart Hospital and ICON, discusses the critical role of improvement in quality of life in assessing drugs that are funded on the PBS, the nuances around clinical trial endpoints and the need for surrogate endpoints that accurately predict for OS and a reimbursement system that brings beneficial treatments to patients faster. Professor Nick Pavlakis, Chair of TOGA and Medical Oncologist at Royal North Shore Hospital and Genesis Care and Dr Deme Karikios, Immediate Past Chair of MOGA and Medical Oncologist from Nepean Hospital Sydney join the conversation. https://jamanetwork.com/journals/jama/article-abstract/2817337

In this episode of ‘Safeguarding Healthcare', Dr David Rankin delves into the complexities of medical administration with guest Dr Bahare Moradi, the Acting Director of Medical Services at the Royal North Shore Hospital in northern Sydney. Together, they dissect a common scenario involving a surgical registrar facing a challenging appendectomy. Dr Moradi highlights the delicate balance between patient safety and providing learning experiences for trainees, emphasising the need for structured support systems within hospitals. They discuss strategies for ensuring young doctors seek help when needed and navigating the dynamics between junior and senior staff. Disclaimer: The views, thoughts, and opinions expressed in the following Podcast are the speaker's own and do not represent the views, thoughts, and opinions of the Royal Australasian College of Medical Administrators (RACMA). The material and information presented here is for general information purposes only, and should not be considered health, legal or financial advice. The cases discussed in the Podcast may be specific to the speaker's organisation or location, and may not be applicable to other organisations, states, territories or countries. RACMA does not endorse, approve, recommend, or certify any information, product, process, service, or organisation presented or mentioned in this Podcast, and information from this Podcast should not be referenced in any way to imply such approval or endorsement. RACMA will not be held responsible for any losses, damages, or liabilities that may arise from the use of this Podcast. The Podcast may contain descriptions of health incidents that may be graphic and triggering for some people, so listener discretion is advised.See omnystudio.com/listener for privacy information.

Neoadjuvant immunotherapy is transforming patient care in the field of melanoma. New research recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting is set to change melanoma treatment protocols globally, and likely to have significant impact on treatment for other cancers too. In this podcast, A/Prof Matt Carlino leads an engaging discussion with MIA's Prof Georgina Long AO, A/Prof Alex Menzies and A/Prof Alex van Akkooi as they discuss the pivotal results from the NADINA trial and how this will undoubtedly change the standard of care for Stage III melanoma patients. They also discuss the practical implications for implementing this treatment regime, including relevant patient populations, toxicity, impacts for surgery and future directions. This podcast is suitable for Medical Oncologists, Surgical Oncologists, Pathologists, Researchers, GPs Oncology Nurses and other healthcare professionals. It is produced by Melanoma Institute Australia. SPEAKERS A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals | Clinical Associate Professor, The University of Sydney Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney A/Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney A/Prof Alexander van Akkooi - Associate Professor in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal Prince Alfred Hospital, The University of Sydney PUBLICATIONS Blank C, Lucas MW, Scolyer RA, et al. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. N Engl J Med 2024. DOI: 10.1056/NEJMoa2402604 Patel SP, Othus M, Chen Y, et al. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med 2023;388:813-823. FURTHER EDUCATION Podcast: Neoadjuvant immunotherapy: Revolutionising melanoma treatment Video: The critical role of standardised pathological assessment in neoadjuvant therapy for melanoma: A guide for Pathologists Conference: 2024 Australasian Melanoma Conference Please note that this podcast was accurate at the time of recording (2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA's Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

On this week's episode we are super excited to be introducing you to our next special guest Host and Social Worker, Jessica Bakon. Jessica is a qualified Social Worker who holds an (Honours) degree from the University of New South Wales. As a new graduate, she worked across both private and public hospitals within the Northern Sydney Local Health District such as at Royal North Shore Hospital. This is where Jessica found passion in utlising evidence- based treatments with patients such as Narrative Therapy, Cognitive Behavioural Therapy and Solution Focused Therapy. Jessica was also trained at Royal North Shore Hospital as a student and had the opportunity of working for BodyMatters Australasia, on her second University internship. This is where Jessica was offered the incredible opportunity to host and produce the ‘Understanding Body Matters Podcast' after the podcast was so beautifully started and crafted by Madison Prubela. Where Jessica has been able to be involved in sharing stories of hope, lived experience, education, professional development, advocacy, wellbeing content and awareness for eating disorders. After a year of working within the healthcare system and gaining the experience she was hoping for Jessica has now gone back to University to complete her Masters of Counselling and Psychotherapy. Hoping to support people in the field of eating disorders and within schools with a special interest for working with adolescents.   A little background about Jessica, she grew up on the Northern Beaches and spent her young working years enjoying her studies, volunteering for charities, and finding a passion in supporting people. However, during her teen years Jessica found herself impacted by disordered eating as a result of an adverse early childhood, social influences and the impact of diet culture. That is why on this week's episode our Host Jessica will be sharing her story with disordered eating, her upbringing, and the reason for her passions in hosting the ‘Understanding Body Matters Podcast'. Jessica also shares the details of how receiving required support, addressing the adverse childhood experiences and having positive role models in her life really helped her along her journey.   In this week's episode Jessica will also disclose brief elements of family domestic violence, strength, and success despite significant challenges faced. Where Jessica thanks the many guests on the podcasts who have been so vulnerable in being able to provide awareness for eating disorders, mental health, and overall wellbeing. This is where Jessica shares her value for learning, education, teachers, supervisors, mentors, and positive role models within her life. As the support from these people were all the main components of Jessica being able to be the person she is today. As someone who now loves and values the role that food can have in her life Jessy now shares her story of gratitude for her recovery and the appreciation that she has for her life. So, on that note, please welcome our next special guest host, Jessy!   Podcast Summary   1.    The impact of adverse childhood experiences 2.    Friendships with people who engaged in disordered eating 3.    Learning to drink alcohol in a binge drinking culture in Australia   4.    Transitional periods 5.    The power of support, role modelling and positive people 6.    Education, awareness, and advocacy in eating disorders  BodyMatters Australasia Website: ⁠⁠⁠⁠⁠⁠⁠https://bodymatters.com.au/⁠⁠⁠⁠⁠⁠⁠ BodyMatters Instagram: @bodymattersau Butterfly Foundation Helpline: Call their National Helpline on ⁠⁠⁠⁠⁠⁠⁠1800 33 4673⁠⁠⁠⁠⁠⁠⁠. You can also ⁠⁠⁠⁠⁠⁠⁠chat online⁠⁠⁠⁠⁠⁠⁠ or ⁠⁠⁠⁠⁠⁠⁠email

On this week's episode we are super excited to be introducing you to our next special guest Host and Social Worker, Jessica Bakon. Jessica is a qualified Social Worker who holds an (Honours) degree from the University of New South Wales. As a new graduate, she worked across both private and public hospitals within the Northern Sydney Local Health District such as at Royal North Shore Hospital. This is where Jessica found passion in utlising evidence- based treatments with patients such as Narrative Therapy, Cognitive Behavioural Therapy and Solution Focused Therapy. Jessica was also trained at Royal North Shore Hospital as a student and had the opportunity of working for BodyMatters Australasia, on her second University internship. This is where Jessica was offered the incredible opportunity to host and produce the ‘Understanding Body Matters Podcast' after the podcast was so beautifully started and crafted by Madison Prubela. Where Jessica has been able to be involved in sharing stories of hope, lived experience, education, professional development, advocacy, wellbeing content and awareness for eating disorders. After a year of working within the healthcare system and gaining the experience she was hoping for Jessica has now gone back to University to complete her Masters of Counselling and Psychotherapy. Hoping to support people in the field of eating disorders and within schools with a special interest for working with adolescents.   A little background about Jessica, she grew up on the Northern Beaches and spent her young working years enjoying her studies, volunteering for charities, and finding a passion in supporting people. However, during her teen years Jessica found herself impacted by disordered eating as a result of an adverse early childhood, social influences and the impact of diet culture. That is why on this week's episode our Host Jessica will be sharing her story with disordered eating, her upbringing, and the reason for her passions in hosting the ‘Understanding Body Matters Podcast'. Jessica also shares the details of how receiving required support, addressing the adverse childhood experiences and having positive role models in her life really helped her along her journey. In this week's episode Jessica will also disclose brief elements of family domestic violence, strength, and success despite significant challenges faced. Where Jessica thanks the many guests on the podcasts who have been so vulnerable in being able to provide awareness for eating disorders, mental health, and overall wellbeing. This is where Jessica shares her value for learning, education, teachers, supervisors, mentors, and positive role models within her life. As the support from these people were all the main components of Jessica being able to be the person she is today. As someone who now loves and values the role that food can have in her life Jessy now shares her story of gratitude for her recovery and the appreciation that she has for her life. So, on that note, please welcome our next special guest host, Jessy!   Podcast Summary: 1. The impact of adverse childhood experiences 2. Friendships with people who engaged in disordered eating 3. Learning to drink alcohol in a binge drinking culture in Australia   4. Transitional periods 5. The power of support, role modelling and positive people 6. Education, awareness, and advocacy in eating disorders Links from the episode and to BodyMatters: BodyMatters Australasia Website: ⁠⁠⁠⁠⁠⁠⁠https://bodymatters.com.au/⁠⁠⁠⁠⁠⁠⁠ BodyMatters Instagram: @bodymattersau Butterfly Foundation Helpline: Call their National Helpline on ⁠⁠⁠⁠⁠⁠⁠1800 33 4673⁠⁠⁠⁠⁠⁠⁠. You can also ⁠⁠⁠⁠⁠⁠⁠chat online⁠⁠⁠⁠⁠⁠⁠ or ⁠⁠⁠⁠⁠⁠⁠email

Mucosal melanoma is a rare and aggressive form of melanoma that arises from the mucous membrane. In this podcast, we focus on mucosal melanoma of the head and neck. Led by A/Prof Sydney Ch'ng, our multidisciplinary experts discuss how it differs from cutaneous melanoma, staging of mucosal melanoma, management of the disease and future treatments. The discussion concludes with a case study to summarise key learnings. This podcast is suitable for Plastic Surgeons, Surgical Oncologists, Dermatologists, Medical Oncologists, Pathologists, GPs, Nurses and other healthcare professionals. SPEAKERS A/Prof Sydney Ch'ng - Plastic & Reconstructive Surgeon and Head & Neck Surgeon, Melanoma Institute Australia | Associate Professor of Surgery, The University of Sydney Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney A/Prof Raewyn Campbell - Rhinologist and Anterior Skull Base Surgeon |Associate Professor, Macquarie University Dr Robert Rawson - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital Prof Angela Hong - Radiation Oncologist, Melanoma Institute Australia | Clinical Professor, The University of Sydney Please note that this podcast was accurate at the time of recording (March 2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA's Education Program is proudly supported through unrestricted educational grants from MSD, BMS and HEINE.

In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives hosts are joined by Brendon Neuen, MBBS, PhD, nephrologist and director of the Kidney Trials Unit at Royal North Shore Hospital and senior research fellow at The George Institute for Global Health. During the episode, Neuen talks about the FLOW trial, topline results, how the rapid advancement in pharmacotherapies has altered conversations around management, the concept of 4 pillars of GDMT for CKD in type 2 diabetes, and how to approach sequencing of these therapies. Video Version: https://www.hcplive.com/view/diabetes-dialogue-flow-trial-and-chronic-kidney-disease-updates-with-brendon-neuen-mbbs-phd Episode Highlights 00:32 - Neuen Introduction 01:55 - FLOW Trial 05:15 - Pillars of CKD Therapy 16:15 - Need for New Guidelines 21:15 - Barriers to Uptake 24:50 - Need for Screening

The process of identifying which patients with acute myeloid leukemia (AML) can benefit from allogeneic stem cell transplantation in first complete remission (CR1) has taken a step forward thanks to analysis of the UK NCRI AML17 and AML19 studies, reported at the 65th ASH Annual Meeting and Exposition. Patients who achieved molecular residual disease (MRD) negativity in their peripheral blood were at low risk of relapse, and had no benefit from allogeneic transplant in CR1, including those with the FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication mutation of the NPM1 (nucleophosmin 1) gene, that is generally considered to be a marker of poor risk. Peter Goodwin spoke with Jad Othman, MBBS, from King's College London and the Guy's and St Thomas' Hospital in London, and now based at the Royal North Shore Hospital in Sydney, Australia. Othman explained how testing for the FLT3 mutation of the NPM1 gene can be used along with assessment of molecular MRD to help choose patients who can benefit from transplant and spare those for whom the risk/benefit ratio is adverse.

Jonathan is joined by Simon Fleming, orthopaedic surgeon, Royal North Shore Hospital, Sydney, Australia, and Fellow of the Royal College of Surgeons of England. Passionate about improving the quality and culture of healthcare, Simon discusses advocating for increased education standards, and his groundbreaking work to drive out bullying, discrimination, and harassment in healthcare.   Use the following timestamps to navigate the content in this episode:   (00:00)-Introduction  (02:12)-Fleming the orthopod   (08:05)-Training and practicing in Britain and Australia  (13:40)-Similarities and dissimilarities  (15:56)-Rocking the boat   (21:28)-Bullying and discriminatory behaviours in healthcare  (23:11)-The BOTA census  (26:09)-TEDx NHS  (29:14)-Holding sexual predators accountable   (34:00)-Pronouns  (37:35)-#OrthoTwitter   (40:35)-Flawed assessment in healthcare  (43:46)-Influencing the next generation  (46:36)-Three wishes for the future of healthcare 

In this Creative Careers in Medicine podcast episode, Dr Elise Putt speaks with Dr Jo Braid, who reflects on her career journey as a rehabilitation medicine physician and a burnout recovery coach.Dr Braid, operating out of Orange, New South Wales, splits her time between the Central West Brain Injury Rehabilitation Programme and her coaching business. Her medical practice is centred on aiding those with traumatic brain injuries to regain their roles in the community, while her coaching focuses on guiding healthcare workers through burnout.Within her varied schedule, Dr Braid consults biweekly at Bathurst Health Service, coaches around ten clients weekly, and manages her podcast and administrative duties. Tennis remains a consistent part of her life, anchoring her weekly routine.Her medical career, prompted by her uncle's encouragement, commenced at Nottingham Medical School. Her journey took her from the UK to Sydney's Royal North Shore Hospital, driven by familial ties to Australia and a quest for a balanced lifestyle. Although initially drawn to anaesthesia, the hands-on nature and calmer pace of rehabilitation medicine steered her path.Dr Braid's pivot to rehabilitation medicine and subsequent experience with burnout in her clinic led to a career-defining shift during the pandemic, culminating in her coaching and podcasting ventures from October 2021.Dr Braid's shift to coaching and podcasting shows her strength and ability to enjoy different kinds of work in medicine. Her dedication to helping people get over burnout highlights her as a guiding light for healthcare workers looking at different career paths.To get more CCIM, subscribe so you never miss an episode, join our Facebook community and subscribe to our newsletter!Website: https://creativecareersinmedicine.com/Facebook: https://www.facebook.com/CreativeCareersInMed/The CCIM Podcast is a proud member of the Talking HealthTech Podcast Network - the premier audio destination for cutting-edge insights and thought leadership in healthcare delivery, innovation, digital health, healthcare ICT, and commercialisation. Learn more at www.talkinghealthtech.com/podcast/network.

On this week's special episode hear from experts in weight loss and osteoarthritis, including content from: Stephen Messier - Losing weight and osteoarthritis– why and how? (Season 1, Episode 4)Rosie Venman - Implementing dietary change (Season 1, Episode 20)Stephen Messier has been at Wake Forest University for 36 years. He is the Director of the J.B. Snow Biomechanics Laboratory and teaches undergraduate biomechanics and human gross anatomy as well as graduate biomechanics. Dr. Messier has 26 years of clinical trial experience concerning osteoarthritis (OA) of the knee; his team of clinicians and researchers are recognized for their research regarding the effects of weight loss and exercise upon knee OA pain, function, strength, and gait biomechanics.Rosie Venman is a clinical Dietitian working at Royal North Shore Hospital. Rosie received her Bachelor's degree in Food Science and Human Nutrition from the University of Newcastle and a Masters in Nutrition and Dietetics from Sydney University. At Royal North Shore Hospital she has been working as the Osteoarthritis Chronic Care Program Dietitian for the last 4 years and has a keen interest in improving weight loss outcomes for this patient group.CONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcast Hosted on Acast. See acast.com/privacy for more information.

Professor Christopher Little is director of the Raymond Purves Bone and Joint Research Labs at the Kolling Institute of Medical Research at Royal North Shore Hospital, Australia. Chris is a qualified Veterinarian with specialist surgery training and ACVS certification. Chris's research interests focus on defining the biochemical and molecular mechanisms of joint pathology in OA, and tendon and intervertebral disc degeneration, and are based on the belief that it is only though a better understanding the mechanisms that drive the initiation and progression of these diseases that new therapies can be developed. Chris is recognized internationally for his expertise in the development and use of animal models of bone and joint disease.CONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review! Hosted on Acast. See acast.com/privacy for more information.

Sentinel node biopsy (SNB) plays a key role in assessing the prognosis of melanomas. In this fireside chat from our new SNB Training Program (Sentinel Node Biopsy: From guidelines to practice), MIA's Prof Georgina Long AO, Prof John Thompson AO and A/Prof Sydney Ch'ng discuss: the history of SNB in the management of melanoma its current role in the stratification of patients into those who may benefit from adjuvant therapies verses those for whom active surveillance is more appropriate other potential benefits of SNB, including the likelihood of SNB itself reducing the risk of nodal recurrence. This podcast is suitable for Surgeons, Medical Oncologists, General Practitioners and other healthcare professionals. SPEAKERS A/Prof Sydney Ch'ng - Plastic & Reconstructive Surgeon and Head & Neck Surgeon, Melanoma Institute Australia | Associate Professor of Surgery, The University of Sydney Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney Prof John Thompson AO - Emeritus Professor of Melanoma and Surgical Oncology, The University of Sydney | Senior Surgeon, Melanoma Institute Australia Please note that this podcast was accurate at the time of recording (July 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

He is a graduate of the UMDNJ- Robert Wood Johnson Medical School (Rutgers Medical School). He did his residency at the University Of Texas Medical School's Department of Anesthesiology and interventional Fellowship with world-renowned specialist, Professor Michael Cousins, at the Royal North Shore Hospital in Sydney, Australia. Dr. Grover also enjoys his work as a television medical correspondent with Fox news, CNN and has been featured on the Discovery Channel, NBC, ABC, CBS and PBS. In response to his work in Pain Management and humanitarian efforts, he was given a national award at the White House from President Clinton and First Lady Hillary Clinton.

In this TOGA Podcast, Australian medical oncologist, Associate Professor Chee Lee, St George Hospital, Kogarah, is joined by medical oncologist Dr Tristan Barnes, Royal North Shore Hospital, Sydney, and Dr Alex Davis, PhD candidate and medical oncologist at Chris O'Brien Lifehouse, Sydney. They discuss treatment of patients with non-small cell lung cancer with KRAS mutations, the role of co-mutations, and biomarkers that are negative predictors of response. Furthermore, the speakers give an update on current clinical research and approval status of KRAS inhibitors as well as the clinical need for the availability of KRAS inhibitors in Australia.

Sarah Webb is an ICU Nurse Practitioner and was the driving force behind the creation of an ICU NP model of care at Royal North Shore Hospital, Sydney. Sarah has over 18 years experience in Intensive Care where she has worked as a Clinical Nurse Specialist, ICU Clinical Coordinator, ICU Clinical Educator and Resuscitation CNC. She has also worked as a midwife and in aeromedical retrieval. Since 2014, Sarah has been working as an NP in ICU, building the core practice areas of an intensive care NP and promoting the nurse practitioner role. Sarah has completed a Master of Nursing (Intensive Care), a Graduate Diploma of Midwifery and a Master of Nursing (Nurse Practitioner). Sarah has a particular interest empowering nursing to build advanced clinical practice in intensive care. Link to QR Code and contact details:https://nswhealth.sharepoint.com/:b:/s/RNSHICUNPService-NSLHD/EfP0l1xbFHZJgAXJI5zOfzIBxkCnSEkIdAsufDcoTSvaTw

Putting the trial on trial? Not really, but join us and the ludicrously accomplished Prof Simon Finfer (with special guest appearances by his beloved dogs) for this review of all things Clinical Trial. Why we need them, how to design them, what they tell us and what they don't.   Professor Simon Finfer works at Sydney's George Institute, Royal North Shore Hospital and University New South Wales. He has led/co-led many of the last two decade's  landmark clinical trials in icu (fluid administration, glycemic control, steroid use...you name it).  

In this TOGA Podcast, Australian medical oncologist Dr Jenny Lee at Chris O'Brien Lifehouse, Sydney, is joined by medical oncologist Professor Nick Pavlakis, from Royal North Shore Hospital in Sydney and Lisa Briggs, Stage IV lung cancer survivor, Author, Osteopath and Exercise Physiologist who provides her own personal experience after being diagnosed with ALK+ non-small cell lung cancer in 2014. They discuss treatment of patients with non-small cell lung cancer with ALK mutations, the latest updates on ALK targeted therapies, the emergence of resistance, and how the choice of ALK inhibitor should be made between clinician and patient, taking into account potential side-effects, their management and the impact on the particular patient's lifestyle.

The first time most of us heard of monkeypox was in May 2022. The smallpox-like infection appeared to spring from nowhere and make its way through Europe then the Americas, largely within the gay and bisexual community. But the first documented human case of mpox actually occurred in 1970 in Central Africa and it's been endemic ever since. Last year's mpox outbreak eclipsed prior case numbers in just a few months thanks to a newly evolved strain. The count of confirmed cases totalled over 86,000 all around the world and it's a testament to well-coordinated community health in the developed world that the outbreak was reigned in within a few months of the index case in Europe. But alongside this success story, there's also a cautionary tale about global health strategy. Because mpox wasn't taken seriously in endemic countries, an incubator was created for this new strain to emerge. We also discuss the stigma associated with sexually transmitted infections and the pros and cons of applying this label. GuestsDr Vincent Cornelisse FRACGP FAChSHM PhD (Royal Prince Alfred Hospital, Royal North Shore Hospital, Sydney; Kirby Institute, UNSW)Dr Massimo Giola FRACP FAChSHM PhD (Te Whatu Ora, Tauranga, Rotorua)ProductionProduced by Mic Cavazzini DPhil. Recording assistance in Tauranga from Melissa Cox, Mockingbird Music Studios. Editorial feedback kindly provided by Dr Aidan Tan and Dr David Arroyo. Music licenced from Epidemic Sound includes ‘Cocktail by Major Tweaks, ‘Broke No More' by Cushy, ‘Temple of Ruhnha' by ELFL and ‘Razzamatazz' by Jules Gaia. Music courtesy of Free Music Archive includes ‘Out of the Skies, Under the Earth' by Chris Zabriskie, Image by Flashpop licenced from Getty Images. Please visit the Pomegranate Health web page for a transcript and supporting references. Login to MyCPD to record time spent listening and reading supporting materials. Subscribe to new episode email alerts or search for ‘Pomegranate Health' in Apple Podcasts, Spotify, Castbox, or any podcasting app. 

Our latest podcast explores the innovative approach of neoadjuvant immunotherapy - administering checkpoint inhibitor immunotherapy before the surgical removal of melanoma. This promising approach is creating a buzz among multidisciplinary clinicians and researchers globally as the potential benefits for melanoma patients are being realised. Although neoadjuvant therapy is well established in oncology, using immunotherapy in melanoma has revolutionised patient outcomes through significant improvements in overall survival rates. In this engaging podcast, MIA's Prof Georgina Long AO leads a discussion with multidisciplinary world leaders in the neoadjuvant space to discuss: the benefits of checkpoint inhibitor immunotherapy the role of the pathologist in the assessment of neoadjuvant tissue the impact of surgical decision-making as neoadjuvant becomes mainstay treatment options for treatment-refractory patients the role of checkpoint inhibitor immunotherapy in non-melanoma skin cancer. The discussion concludes with case studies to summarise key learnings. This podcast is suitable for Medical Oncologists, Oncologists, Surgeons, Pathologists, Dermatologists, GPs, Oncology Nurses and other healthcare professionals. SPEAKERS: Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney Prof Richard Scolyer AO - Co-Medical Director, Melanoma Institute Australia | Pathologist, Melanoma Institute Australia, Senior Staff Specialist, Royal Prince Alfred Hospital | Clinical Professor, The University of Sydney A/Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia, Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney A/Prof Alexander van Akkooi - Associate Professor in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal Prince Alfred Hospital, The University of Sydney KEY CLINICAL TRIALS SWOG PRADO OpACIN-neo NADINA FURTHER EDUCATION The critical role of standardised pathological assessment in neoadjuvant therapy for melanoma: A guide for Pathologists Please note that this podcast was accurate at the time of recording (February 2023) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA's Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

In this Podcast, Dr Malinda Itchins, Medical Oncologist at Royal North Shore Hospital, Co-Chair of the Advanced Non-Small Cell Lung Cancer Group for TOGA and the Lung Cancer Chair of COSA, is joined by Professor Stephen Fox, Director of Pathology and Head of the Molecular Pathology Laboratory at the Peter MacCallum Cancer Centre in Melbourne Victoria and Professor Michael Millward, Medical Oncologist and Cancer Council Professor of Clinical Cancer Research School of Medicine, University of Western Australia to discuss NGS panels in lung cancer. They discuss the logistics and other considerations behind choosing and implementing NGS panels and the potential future application of this technology in clinical management of NSCLC. Keen to hear more beyond this podcast? Save the date 19 July 2023 for a f2f workshop in Melbourne discussing the various technologies for molecular testing, considerations for implementation and downstream applications. Registration will be part of TOGA ASM 2023 registrations expected to open by April 2023.

Despite recent advances in management of primary uveal melanoma, more than half of patients develop metastatic disease – often with poor outcomes. New therapeutic approaches to metastatic disease are vital. In this podcast, A/Prof Matteo Carlino interviews fellow Medical Oncologist Prof Georgina Long AO and Ophthalmologist A/Prof Max Conway on our latest understanding of the diagnosis and management of early and advanced uveal melanoma, including: presentation and diagnostic process current treatment options and rationale for local therapy in early melanoma determining which patients are suitable for screening for metastatic disease developing a surveillance plan based on risk of recurrence the different activity of systemic therapy in uveal versus cutaneous melanoma importance of the multidisciplinary team activity of tebentafusp in advanced uveal melanoma the current clinical trial landscape. This podcast is suitable for Oncologists, Ophthalmologists, GPs, Oncology Nurses and other healthcare professionals. SPEAKERS A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals Clinical Associate Professor, The University of Sydney Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney A/Prof Max Conway - Ophthalmologist, Save Sight Institute, Sydney Eye Hospital and The University of Sydney RESOURCES Early Ocular Melanoma Patient Information Brochure Advanced Ocular Melanoma Patient Information Brochure Melanoma Education Portal Please note that this podcast was accurate at the time of recording (November 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA's Education Program is proudly supported through unrestricted educational grants from MSD, BMS, Novartis and HEINE.

 Dr May Wong a gastroenterologist from Sydney's Royal North Shore Hospital on ways to combat reflux/heartburn. One in five Australians suffers from this. She also tells us the warning signs if it's something more serious.See omnystudio.com/listener for privacy information.

As a new Fellow, Dr Zainab Naseem was hoping to achieve a more comfortable work-life balance when she came across an advertisement for the New Fellow Rural Placement – or NFRP – on the College's website. The NFRP is an initiative delivered by RACS through the Specialist Training Program, funded by the Australian Department of Health. Dr Naseem was at Sydney's Royal North Shore Hospital at the time when she applied for the rural placement at Griffith Base Hospital, in the Riverina region of central New South Wales. Although it was hard to adjust at first, Dr Naseem and her young family have learned to love the regional city.See omnystudio.com/listener for privacy information.

Did you know that 500 million people around the world have osteoarthritis? In those over 55 years of age, a staggering one in three people have osteoarthritis. While many people may well suffer in silence or become isolated from the disease, it's important to recognise that you are not alone in your experience of living with this disease. Professor Lyn March joins us on this episode to discuss the burdn of OA in Australia and worldwide. Professor Lyn March has a conjoint appointment with the University of Sydney and the Royal North Shore Hospital in the Sydney Medical School and Professorial Department of Rheumatology. She has 20 years of experience as a consultant rheumatologist and has remained very active in research and teaching. She has had a lead role in her profession holding Presidential and other honorary executive positions in both the NSW and Australian Rheumatology Associations and is co-chair of the NSW Musculoskeletal Network for the recently formed NSW Health Agency for Clinical Innovation. She is the International Musculoskeletal Expert Group Leader for the current Global Burden of Diseases StudyRESOURCESThe Institute for Health Metrics and EvaluationBurden of osteoarthritis in India and its states, 1990-2019: findings from the Global Burden of disease study 2019CONNECT WITH LYNTwittter: @lynmarch1Australian Arthritis and Autoimmune Biobank CollaborationCONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! See acast.com/privacy for privacy and opt-out information.

He is a graduate of the UMDNJ- Robert Wood Johnson Medical School (Rutgers Medical School). He did his residency at the University Of Texas Medical School's Department of Anesthesiology and interventional Fellowship with world-renowned specialist, Professor Michael Cousins, at the Royal North Shore Hospital in Sydney, Australia. Dr. Grover also enjoys his work as a television medical correspondent with Fox news, CNN and has been featured on the Discovery Channel, NBC, ABC, CBS and PBS. In response to his work in Pain Management and humanitarian efforts, he was given a national award at the White House from President Clinton and First Lady Hillary Clinton.

The identification of molecular subtypes of non-squamous NSCLC continues to grow, spurring the development of targeted therapies designed to target these mutations and prevent the growth of the cancer. People with advanced NSCLC that possess one of these ‘actionable' mutations and can access targeted treatments can live for many years with very manageable side effects. However, the technology to identify these actionable mutations in a single test and the targeted treatments are not yet accessible to all people with advanced NSCLC.In this TOGA podcast, we explore access to molecular diagnostics and treatments across ANZ: the past, present, future. Chaired by Professor Nick Pavlakis: Medical Oncologist, Royal North Shore Hospital, Genesis Care and Chair of Thoracic Oncology Group of Australasia ; joined by Dr Laird Cameron: Medical Oncologist Auckland Hospital and Canopy Cancer Care and TOGA Scientific Committee New Zealand representative and Dr Renuka Chittajallu, Medical Oncologist Riverina Cancer Care Centre, Griffith Base Hospital, Genesis cancer care, Kingswood, Director of Clinical Trials, Riverina Cancer Care Centre.In Australia, the TOGA ASPiRATION study is evaluating the impact of providing comprehensive genomic profiling and access to targeted therapies, with the hope that this will provide the evidence for widespread reimbursement for testing and treatments for patients where an actionable mutation is identified.https://thoraciconcology.org.au/aspiration/ 

Physical Activity with Osteoarthritis - Prof David Hunter (Pt2) Professor Hunter is a rheumatology clinician researcher whose main research focus has been clinical and translational research in osteoarthritis (OA). He is the Florance and Cope Chair of Rheumatology and Professor of Medicine at University of Sydney and the Royal North Shore Hospital. He is ranked as the worlds leading expert in osteoarthritis on Expertscape.com since 2014. He is on the editorial board for Arthritis and Rheumatology, Osteoarthritis and Cartilage, Arthritis Care and Research and part of the review committee for OA for the American College of Rheumatology, EULAR and OARSI scientific meetings. Dr Hunter has over 500 peer reviewed publications in international journals, numerous book chapters, is the section editor for UpToDate Osteoarthritis and has co-authored a number of books, including books on self management strategies for the lay public. --- This podcast episode is sponsored by Fibion Inc. | The New Gold Standard for Sedentary Behaviour and Physical Activity Monitoring Learn more about Fibion: fibion.com/research --- Collect, store and manage SB and PA data easily and remotely - Discover new Fibion SENS Motion: https://sens.fibion.com/

Elliot is an intensive care nurse practitioner, working at Royal North Shore Hospital in Sydney NSW. Elliot has worked in ICU for 10 years, and has post-graduate qualifications in critical care, and a Master of Nursing (Nurse Practitioner) from the University of Sydney. Elliot has sub-specialty interests in vascular access and extracorporeal membrane oxygenation (EMCO). He is a member of the ACI NSW ECMO Advisory Group, runs the ECMO course at RNSH, and is the nursing lead for ECMO in the ICU at RNSH.Elliot has been involved in post-graduate teaching for many years, initially as a Clinical Fellow for the Faculty of Health at University of Technology, Sydney, and now for Sydney Nursing School, Faculty of Medicine and Health at the University of Sydney as a Casual Academic. In this role, Elliot teaches on the Nurse Practitioner Master Program, and has helped with subject redesign.Elliot is also a member of the Clinical Practice Committee for NSW Ambulance Service, where he provides expert advice relating to nursing practice and his relevant areas of specialization. He is also assisting NSW Ambulance with a research project currently, and is a key advisor on nursing matters in general for the organization.Elliot has an interest in research, having been involved in numerous local studies, site co-investigator for a large multinational registry study, and has authored a number of papers related to vascular access and the ICU Nurse Practitioner model of care.

An important factor has been missing in the assessment of pain, according to our guest this week on The Tea Room.Dr Manasi Murthy Mittinty practices at the Pain Management Research Institute at the Royal North Shore Hospital. In this episode she shares what she's recently learned about pain.“More and more research shows us that we need to take a biopsychosocial approach to managing pain,” she says. “It is very much a person-centered approach. ‘One size fits all' doesn't work for pain.”Dr Mittinty's pain research has taken her around the world including studies with patients from India, First Nations people from Appalachia in the United States and with Aboriginal and Torres Strait Islander people from South Australia.She says culture and spirituality are missing aspects in the conventional assessment and treatment of pain.Dr Mittinty has some helpful tips for GPs, including a new understanding of conventional pain assessment scales.“Most of the pain measurement we use clinically and research has never been adapted for Indigenous communities. The questions we pose to the patient do not always relate to, or reflect, their lived experiences,” she says.Dr Mittinty's learnings from the research were personal as well as professional. She says she was honoured to hear the stories from Indigenous elders and acquired insight into the multiple daily challenges being dealt with alongside proactive pain management.“I saw immense resilience in patients figuring out ways to help themselves deal with their pain,” she says. “Rather than focusing on the pain the patients would just keep moving on and doing the next thing that was required in their life. It was very inspiring for me."

Cancer drugs have rapidly evolved in the last decade. Alongside the significant benefits are new toxicity profiles that clinicians need to be aware of and manage.In this podcast, A/Prof Carlino interviews fellow Medical Oncologist Prof Georgina Long AO on the adverse events/toxicities associated with targeted therapies (combination BRAF/MEK inhibitors) and immunotherapies (anti-PD-1, anti-LAG-3 and anti-CTLA-4), particularly in melanoma, and how they should be managed.Some key points brought up during this deep dive in toxicity:With targeted therapies, cessation of treatment usually reverses the toxicity.Immunotherapy toxicities are driven by the immune system rather than the drugs themselves, and as such, cessation of treatment does not automatically resolve toxicity. Most toxicities need active treatment to resolve.It is crucial to educate your patients regarding temporarily ceasing therapy in response to toxicity, particularly fever.It is important to recognise that immunotherapy toxicity is not necessarily treated the same as the autoimmune disease it may mimic.Understanding the patient's history is crucial to identify if symptoms are a direct result of treatment.Ceasing immunotherapy treatment in the setting of toxicities does not mean you lose efficacy.It is important to understand the risk versus benefit when assessing your patient for re-challenge with immunotherapy after a toxicity.Medical Oncologists should have a referral network of experts for managing your patient's toxicities.This podcast is suitable for Oncologists, Emergency Medicine Physicians, GPs, Oncology Nurses and other healthcare professionals.SPEAKERSProf Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of SydneyA/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals Clinical Associate Professor, The University of SydneyPlease note that this podcast was accurate at the time of recording (May 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.MIA's Education Program is proudly supported through unrestricted educational grants from: MSD, Bristol Myers Squibb, Novartis and HEINE.

Professor Hunter is a rheumatology clinician researcher whose main research focus has been clinical and translational research in osteoarthritis (OA). He is the Florance and Cope Chair of Rheumatology and Professor of Medicine at University of Sydney and the Royal North Shore Hospital. He is ranked as the worlds leading expert in osteoarthritis on Expertscape.com since 2014. He is on the editorial board for Arthritis and Rheumatology, Osteoarthritis and Cartilage, Arthritis Care and Research and part of the review committee for OA for the American College of Rheumatology, EULAR and OARSI scientific meetings. Dr Hunter has over 500 peer reviewed publications in international journals, numerous book chapters, is the section editor for UpToDate Osteoarthritis and has co-authored a number of books, including books on self management strategies for the lay public. --- This podcast episode is sponsored by Fibion Inc. | The New Gold Standard for Sedentary Behaviour and Physical Activity Monitoring Learn more about Fibion: fibion.com/research --- Collect, store and manage SB and PA data easily and remotely - Discover new Fibion SENS Motion: https://sens.fibion.com/

Welcome to the second episode of the podcast Challenges that Change Us, where we interview people who have overcome or dealt with challenges to find out how dealt with them and what lessons they have learnt.For this episode I'm really excited to introduce you to one of the most incredible men I know, James Horsburgh Aka Teddy. His perseverance, determination and positive attitude is admired by so many.Teddy and I both lived on campus together while studying law.On the 7th of October 2004 I found out that something had gone seriously wrong for Teddy after he had dived into a water fountain after a night out with our mate and was airlifted to Royal North Shore Hospital after dislocating his neck.In today's episode Teddy shares:- Exactly what it was like in the initial moments of this horrible trauma- How he kept going and stayed afloat mentally in some of the darkest moments while in hospital- How he personally embraces and deals with negativity in a way that allows him to lead a positive life.Key Quotes“If you focus on the negative then of course it's going to be negative. But if you focus on the positive then life's much more enjoyable I've found”“If you have a positive frame of mind and you have the ability to focus on what's important and distract yourself from those things that are getting you down, then the rest of your life seems to have a positive overtone to it”“Allow yourself to be negative for 5 or 10 minute, but have a strategy to diver your mind”You can find James working with McIntosh McPhillamy & Co legal services here: https://www.mcmc.com.au/james-horsburghAnd you can also find him on linkedin: https://www.linkedin.com/in/james-horsburgh-429b4930/?originalSubdomain=auFor Ali's businesses you can find them through their websiteswww.trialtitudeperformance.com.auwww.altitudefitnessarmidale.com.auOr you can follow them on Instagram:@trialtitudeperformance@Veravidyayoga@Altitudefitnessarmidale Hosted on Acast. See acast.com/privacy for more information.

Dr. Khairil Musa is a Senior Intensive Care Registrar from Royal North Shore Hospital and an ICU Field Doctor with Doctors Without Borders/Médecins Sans Frontières (MSF). Khairil was deployed to Yemen and Iraq in 2020 as part of MSF's COVID19 response and also worked in MSF's Trauma Hospital in Aden. In his downtime Khairil is passionate about the performing arts and is a classically trained dancer and the Creative Lead for the SMACC/CODA Conference opening ceremonies.In this episode, we discuss his journey into intensive care as a specialty, the application process and deployment for MSF, his work in Yemen and Iraq with MSF, the post-traumatic stress and burnout he suffered, his recovery, and his love for classical ballet. As always, if you have any feedback or queries, or if you would like to get in touch with the speaker, feel free to get in touch at doctornos@pm.me.Audio credit:Bliss by Luke Bergs https://soundcloud.com/bergscloudCreative Commons — Attribution-ShareAlike 3.0 Unported — CC BY-SA 3.0Free Download / Stream: https://bit.ly/33DJFs9Music promoted by Audio Library https://youtu.be/e9aXhBQDT9YSupport the show (https://www.patreon.com/doctornos)

This is part 2 of my chat with Bill Bestic.Bill is a former soldier in the NZ SAS and currently is an Anaesthetist at Royal North Shore Hospital in Sydney and is a recently qualified commercial helicopter pilot.I would recommend listening to Part 1 as it will provide some context to this half of the conversation 

This week I have something a little different, I am joined by Bill Bestic and this session will be broken in to part 1 and part 2 as he was kind enough to spend a fair amount of time with meI have always had a fascination with the SAS and that is how I stumbled across Bill was searching for podcasts with SAS soldiers. I was immediately captivated by Bills humility and his ability to reflect on what he had learnt, take a look at himself first and then evolve his skillsWhat I also found fascinating was once Bill finished in the SAS he trained to become a doctor and then an anaesthetist which he now does at Royal North Shore Hospital in Sydney , oh and also he become a commercial helicopter pilot over the last couple of years too!I was intrigued to dig into the different leadership styles and environments between general population and the military and if there is stuff we could learn from either environment. Bill is a fantastic learner and thinker, there is so much to learn from this episode I trust you will enjoy it and part 2 will come out next week.

Mike Freelander is the Labour MP for Campbelltown N.S.W. https://www.drmikefreelander.com.au. Mike has been a paediatrician in Campbelltown for 37 years and has dedicated his life's work to ensuring that our children get the greatest possible start in life. Mike completed his residency at the Royal North Shore Hospital before training as a paediatrician at the Royal Alexandra Hospital for Children in Camperdown. Mike and his wife Sharon relocated to the Macarthur Region in 1984, where they raised their six children. Mike started working at Campbelltown Hospital at this time, where he served as Head of Paediatrics from 1986 until 2013. Mike has been a paediatrician in Campbelltown for 37 years and has dedicated his life to ensuring that our children get the greatest possible start in life. Mike established practises in Campbelltown and Camden after noticing that the region's rising demands were not being served. Despite his busy schedule as a paediatrician, Mike still finds time to give back to his profession as a lecturer at Western Sydney University. Rumble https://rumble.com/register/shiels100/ TEEPUBLIC http://tee.pub/lic/30oqBso3y2Y Linktree https://linktr.ee/stephenshiels Patreon https://www.patreon.com/stephenshiels?fan_landing=true Redbubble https://www.redbubble.com/people/Shiels900/shop?asc=u&ref=account-nav-dropdown Bandcamp https://stephenshiels.bandcamp.com/album/death-and-life Webtalk https://join.webtalk.co/7070500 --- Send in a voice message: https://anchor.fm/stephen-shiels/message

In this Healthed lecture, Consultant Psychiatrist from Royal North Shore Hospital, Dr Prachi Brahmbhatt, will explain that the rates of remission and recovery after a single schizophrenic episode are good (~80%), but the rates decline with each subsequent episode. As such, maintaining adherence and optimizing symptom control improves physical health outcomes and this is where GPs have a very important role. Dr Brahmbhatt will provide a very useful, practical guide to choosing, initiating, titrating, balancing effectiveness against tolerability, and switching and monitoring for adverse effects. See omnystudio.com/listener for privacy information.

The field of melanoma has experienced a paradigm shift in recent years, with advancements in both diagnosis and management driving improved patient outcomes. Through the power of research, day-to-day practice continues to be transformed.In this lively podcast, two of Australia's leading melanoma experts Prof Richard Scolyer AO and Prof Georgina Long AO discuss:how melanoma management has transformed in the last decadethe challenge of diagnosing melanoma for clinicians and pathologists, and practical ways to help make accurate assessmentsthe importance of stagingwhy sentinel node biopsies are importanthow multidisciplinary care enhances patient outcomesemerging evidence on neoadjuvant treatment and how this will change the way melanoma is managedthe challenge of supportive care and where to find help.In this practical discussion, resources and further education for deeper dives into specific topics are also mentioned, with links below.This podcast is suitable for oncologists, surgeons, dermatologists, skin cancer GPs, GPs, nurses and other healthcare professionals.SPEAKERSProf Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of SydneyProf Richard Scolyer AO - Co-Medical Director, Melanoma Institute Australia | Pathologist, Melanoma Institute Australia, Senior Staff Specialist, Royal Prince Alfred Hospital | Clinical Professor, The University of SydneyDanielle Fischer - Education Program Manager, Melanoma Institute AustraliaLINKS TO RESOURCESMelanoma Risk Prediction ToolsProf John Thompson's presentation: Update on melanoma stagingOrder or download a pocket-sized Melanoma Staging CardProf Richard Scolyer's presentation: Melanoma near misses: Clues to diagnosisDermoscopy module: Techniques in melanoma assessmentInteractive game: DermChallenge: Management.Debate: To shave or not to shave when biopsying melanomaPodcast: Multidisciplinary management of primary melanomaPresentation by Dr Rob Rawson and Dr Michael Rtshiladze: The melanoma pathology report and its impact on clinical managementWiki melanoma guidelines: Clinical practice guidelines for the diagnosis and management of melanomaInteractive module: The current role of sentinel node biopsy in the management of melanomaDebate: The role of sentinel node biopsy is overstated in melanomaSNB Melanoma Risk CalculatorPresentation by A/Prof Robyn Saw and Dr Tom Pennington: Optimal initial management of melanoma in primary care settingsPresentation by Prof Georgina Long: Neoadjuvant therapy in melanoma: The perfect modelPodcast: Neoadjuvant therapy in melanoma with Georgina LongPodcast: The complexities of adjuvant therapy in melanomaPodcast: Management of brain metastases in melanomaHospital Support Services DirectoryMelanoma Support Service DirectoryPatient resources: Patient guides and video for early stage patients

About 1.6 Million Aussies are currently living with dermatitis. Therefore it's probably either affecting you or someone you know well... Today Shazzy is joined by Dr Stephen Shumack, Dermatologist from Royal North Shore Hospital and Associate Professor at the University of Sydney, to chat about the skin condition that affects millions of Aussies each year.  They talk about new treatment options, why and how someone gets eczema and what you can do if you're prone to it. THE END BITS CREDITS Host: Sharon 'Shazzy' Hunt Guest: Dr Stephen Shumack Producer: Mikayla Floriano Audio Producer: Leah Porges  GET IN TOUCH: Got a beauty question you want answered?  Email us at youbeauty@mamamia.com.au or call the podphone on 02 8999 9386.  Join our You Beauty Facebook Group here. Want this and other podcasts delivered straight to your inbox? Subscribe to our podcast newsletter. You Beauty is a podcast by Mamamia. Listen to more Mamamia podcasts here. Mamamia acknowledges the Traditional Owners of the Land we have recorded this podcast on, the Gadigal people of the Eora Nation. We pay our respects to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander cultures. Just by reading or listening to our content, you're helping to fund girls in schools in some of the most disadvantaged countries in the world - through our partnership with Room to Read. We're currently funding 300 girls in school every day and our aim is to get to 1,000. Find out more about Mamamia at mamamia.com.au  See omnystudio.com/listener for privacy information.

Welcome to Season 2 of the Spot On podcast.  In Season 1, we focused on the fundamentals of skin cancer, interviewing some of Australia's leading clinicians on the topic. In this season, we're focused more on the human side of a diagnosis.  MSCAN is thrilled to have renowned journalist Deborah Knight involved and interviewing patients about their journey with skin cancer and the road ahead. In this episode you will hear from Professor Alan Cooper; a Clinical Dermatologist himself, who was diagnosed with stage III melanoma which progressed to stage IV.  In this episode, Alan is joined by his treating clinician - Professor Georgina Long.   Professor Alan Cooper Professor Alan Cooper was diagnosed with stage III melanoma in 2013, and despite multiple surgeries and two trials of experimental treatment it progressed to stage IV. The melanoma eventually responded to a combination of radiation therapy and immunotherapy which commenced in early 2017. At the time of diagnosis, Alan was Clinical Professor of Dermatology at the Northern Clinical School of the University of Sydney, and Head of the Department of Dermatology at Royal North Shore Hospital. Over the years he has served in a number of capacities in The Australasian College of Dermatologists and has been involved in the training and assessment of medical students and dermatology advanced trainees. He supervised a research unit and was involved in fund raising for dermatology research through state, national and international foundations. Alan is a Director of MSCAN.   Professor Georgina Long Professor Georgina Long is the Co-Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney. She leads an extensive clinical trials team and laboratory at MIA, with a focus on targeted therapies and immuno-oncology in melanoma. Professor Long is the author of over 370 peer-reviewed publications in clinical and translational research in melanoma.

Welcome to the Thoracic Oncology Group of Australasia Podcast series. Today Mal Itchins, Medical Oncologist from Royal North Shore Hospital discusses ALK therapy choices & considerations when treating ALK NSCLC. Mal is joined by Steven Kao, Medical Oncologist from the Chris O'Brien Lifehouse and Lisa Briggs who has her own personal experience with ALK lung cancer having been diagnosed in 2014, when only limited treatment options were availableWe have seen rapid transformation in treating ALK lung cancer with emerging therapies and new indications over the last decade. We discuss how to choose one treatment over another, optimizing sequencing as well as addressing potential side effects associated with each of the options. Patient preferences, needs and wants are also considered.Two of the associated TOGA trials, ASPiRATION and ALKternate are exploring how molecular testing can monitor emerging mutations and influence treatment decisions, as well as exploring liquid biopsy to search for emerging mechanisms of resistance.https://thoraciconcology.org.au/clinical-trials/Thank you to Pfizer for sponsoring this Podcast.Disclaimer: The opinions, beliefs and viewpoints expressed by the various authors and participants contained in this message do not necessarily reflect the opinions, beliefs and viewpoints of TOGA or official policies of TOGA. Dosage & administration of any treatments mentioned during TOGA medical education may differ between Regions. Please refer to your local prescribing information for further details.

With Martha Gulati, University of Arizona College of Medicine - Phoenix - USA & Anastasia Mihailidou, Royal North Shore Hospital, Sydney - Australia Link to paper Link to editorial

Shabnam Ighani was born in the North of Iran, of Bahá'i faith and with a wonderful childhood, she believed in the equality of men and women and the emphasis on girls education.She was 12 years old when the Islamic Revolution happened in 1979 and the Islamic government took over the country. It was a memorable moment in her life as she remembers she was in secondary school and wearing a nice pink shirt with short grey skirt uniform that changed overnight in to a long black dress and head cover referred to as a “Manto”. Subjected to discrimination, bullying and harassment for being non Muslim, all Bahá'i people with a government job, qualified doctors, nurses, lawyers, teachers and other professions lost their jobs.At the age of 18, she married an over protective and controlling man who slowly made her miserable to where her confidence and self-esteem hit their lowest point and she became physically and mentally sick. She could not make any decision for herself and was subjected to emotional and psychological abuse for many years, leaving Shab with the conclusion that she had no choice but to escape to a free country. She counts herself lucky that Australia gave her that refuge. Her book titled - ‘Fighting for A Future, Trapped Behind the Border' tells her life story. Shab attained her master's degree in nursing specialising in Nursing Management and Clinical Nurse studies, and today works as a Clinical Nurse Specialist at the Royal North Shore Hospital.Shab has a YouTube channel, predominantly in Persian, with more than 3,000 subscribers. Her aim is to help other people who are doing it tough in life and who are looking for answers and a direction.Socials:Website: https://www.shabnamighani.com/LinedIn: Shabnam (Shab) Ighani FB: Fighting For A Future: Trapped Behind The Border @shabnamighaniauthor Insta: Shabnam Ighani @shab_ighani Enjoy the visual here on Youtube

Drugs that target cancer gene mutations or rearrangements have improved outcomes for patients with many different cancers, including lung cancer, melanoma, and others . The challenge is being able to identify these genomic changes in a timely and efficient manner. Next-generation sequencing (NGS) based tumour comprehensive genomic profiling (CGP) that detects a wide range of genomic aberrations is one method being utilized to match patients to relevant targeted therapies against several oncogenic drivers, particularly for lung cancer. Several in-house as well as commercial testing panels are now available that help Medical Oncologists understand the cancer genomic profile of their patients. This information helps inform whether there these patients are likely to respond to a targeted agent, either as standard of care or as part of a clinical trial.In this Podcast, we will discuss some of the challenges that exist in being able to identify these molecular changes. The value of comprehensive genomic profiling for lung cancer patients in Australia will be discussed including the TOGA ASPiRATION study, an observational cohort study to assess the clinical impact of CGP in metastatic lung cancer patients. Professor Nick Pavlakis, TOGA Chair and Senior Staff Specialist in the Department of Medical Oncology at Royal North Shore Hospital and conjoint Professor in the Faculty of Medicine University of Sydney, is joined by Professor Stephen Fox, Head of the Molecular Pathology Laboratory, also currently Director of Pathology at Peter MacCallum Cancer Institute and Professorial Fellow in the Department of Pathology, The University of Melbourne.https://thoraciconcology.org.au/aspiration/Thank you to Roche for sponsoring this Podcast.

Sleep disturbances are common in those with osteoarthritis. Research has postulated that poor night time sleep is associated with increased pain the following day and that sleep disturbances are associated with increased risk for developing or worsening pain in the long-term. The interactions between pain and sleep are complex. On this episode of Joint Action, we are joined by Peter Cistulli to discuss the relationship between sleep and pain and how we can improve sleep. Professor Peter Cistulli holds the ResMed Chair in Sleep Medicine at the University of Sydney, where he leads the Sleep Research Theme within the multidisciplinary Charles Perkins Centre. He heads the Discipline of Sleep Medicine within the Faculty of Medicine and Health. He is also Director of the Centre for Sleep Health & Research in the Department of Respiratory and Sleep Medicine at Royal North Shore Hospital, Sydney. He is an active clinician researcher with 28 years experience in in the fields of respiratory and sleep medicine. His thematic research has focussed on the pathophysiology of Sleep-disordered Breathing, and novel approaches to therapy. RESOURCESThe Sleep Health FoundationSleep Quality and Fatigue Are Associated with Pain Exacerbations of Hip Osteoarthritis CONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! See acast.com/privacy for privacy and opt-out information.

Vol 215, Issue 5: 6 September 2021. Dr Kunwardeep Bhatia is a cardiology advanced trainee at Royal North Shore Hospital in Sydney. He and colleagues from 21 hospitals across four states investigated cardiac complications in patients hospitalised with COVID-19 through January 2021. Their research is available, open access, at https://www.mja.com.au/journal/2021/215/6/incidence-cardiac-complications-patients-hospitalised-covid-19-australia-aus ... Dr Bhatia chats with MJA news and online editor, Cate Swannell.

Delays in diagnosis are one of the main factors associated with reduced survival rates for lung cancer patients. Clinical guidelines have been implemented in some countries to standardize the diagnosis process, better define the time from diagnosis to the beginning of treatment, and to improve clinical results in lung cancer. In Australia, periods of 14 days from the initial referral of the GP to the first specialty consultation, and also from diagnosis to the first treatment are recommended. However, previous reviews showed an average time of 27 days for lung cancer diagnosis, with time distributions below those recommended by international guidelines (ranging from 6 to 45 days). Across all three modalities, a treatment delay of four weeks is associated with an increase in the risk of death.In this TOGA Podcast, we will discuss some of the challenges associated with treatment delay and how we can improve these for lung cancer patients in Australia. Dr Mal Itchins, is a thoracic medical oncologist at Royal North Shore Hospital, GenesisCare, and North Shore Private; Professor Wendy Cooper,  Staff Specialist in Tissue Pathology and Diagnostic Oncology at Royal Prince Alfred Hospital and Mr Phillip Antippa a specialist Cardiothoracic surgeon and the Head of Thoracic Surgical Services at The Royal Melbourne Hospital and the Peter MacCallum Cancer Centre, join us in the conversation.Thank you to Novartis for sponsoring this TOGA Podcast.Reference:ASPiRATION is an observational cohort study to assess the clinical impact of comprehensive genomic profiling in metastatic lung cancer patients. Find more information here: https://thoraciconcology.org.au/aspiration/

Professor David Hunter is the Florance and Cope Chair of Rheumatology and Professor of Medicine at The University of Sydney, and a Staff Specialist at Royal North Shore Hospital and North Sydney Orthopaedic and Sports Medicine Centre. Professor Hunter is the number one ranked expert in osteoarthritis on Expertscape.com with an impressive 532* peer-reviewed publications. He has co-authored several books ranging from the medical textbooks on osteoarthritis to self-management books for patients suffering from osteoarthritis. He is also the section editor for the UpToDate Osteoarthritis page and host of the Joint Action podcast. *Professor Hunter's profile: https://www.sydney.edu.au/medicine-health/about/our-people/academic-staff/david-hunter.html  Joint Action Podcast: https://www.jointaction.info/podcast UpToDate osteoarthritis page: https://www.uptodate.com/contents/table-of-contents/rheumatology/osteoarthritis Is being barefoot, wearing shoes and physical activity associated with knee osteoarthritis pain flares? Data from a usually barefoot Sri Lankan cohort:  https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.14024 Effects of Intensive Diet and Exercise on Knee Joint Loads, Inflammation, and Clinical Outcomes Among Overweight and Obese Adults With Knee Osteoarthritis The IDEA Randomized Clinical Trial:  https://jamanetwork.com/journals/jama/fullarticle/1741824 

New South Wales has recorded 24 new community cases of Covid-19. The new cases take the Sydney outbreak to 195, with 175 linked to the Bondi cluster.Nine of today's new cases were in isolation throughout their infectious periods, NSW Health said in a statement. A further three cases were in isolation for part of their infectious periods. Twelve cases were infectious in the community.NSW Premier Gladys Berejiklian said the fact that almost half of today's new cases were in the community while infectious was a cause of concern."People going about their business, shopping and interacting with others is causing the virus to continue to circulate," she said."If we want the lockdown to succeed, all of us to have minimise our movements, all of us to have minimise our interaction with others, as difficult as that is, to make sure that the lockdown is successful."We know how transmissible this variant of the virus is and we need to respond accordingly," she said.Two cases in Queensland, one in NT, none in Victoria, SA or WAQueensland today recorded two new community cases of Covid-19, bringing the state's outbreak to 20.Of those new cases, one was a close contact linked to the Portuguese restaurant cluster and was already in isolation. The other case is a 37-year-old woman who works at the Qatar check-in counter at Brisbane's International Airport.Queensland Premier Annastacia Palaszczuk said the low case numbers were very encouraging, but warned residents that the state was "not out of the woods yet"."We've got another 24 hours to see what happens over the next 24 hours and will take you tomorrow in relation to whether or not we can [end the] lockdown, but it is very encouraging news at this stage," she said.Infectious diseases physician Paul Griffin told the Courier Mail just one day's figures wasn't enough to make a call on whether the lockdown in the south-eastern parts of Queensland will end on time tomorrow.The Northern Territory today recorded one new community case. That person was a close contact of a known positive case and has been in quarantine throughout his infectious period.Western Australia, Victoria and South Australia all recorded zero community cases today.This is where the outbreak currently stands: NSW has 195 confirmed cases, Queensland has 20 cases, the Northern Territory has 10 cases, Western Australia has four cases and South Australia has five cases.Second nurse at Sydney hospital infectedA second nurse at Sydney's Royal North Shore Hospital has contracted Covid-19.It comes after authorities revealed yesterday a 24-year-old student nurse had tested positive to the virus and worked in the rehabilitation ward at Fairfield Hospital and the and a cardiology and a general abdominal surgery ward at the Royal North Shore Hospital during her infectious period.Those wards were immediately sent into lockdown as authorities rushed to conduct contact tracing.Journalist Ben Fordham revealed this morning three extra wards are now on alert following the second case. The vaccination status of the nurses is not known.Tighter restrictions across AustraliaAround half of the Australian population is in lockdown as multiple states and territories battle rising Covid-19 cases.NSW's Greater Sydney area, the Northern Territory's Greater Darwin and Alice Springs regions, Western Australia's Perth and Peel regions, and the south-eastern parts of Queensland are now all in lockdown due to multiple coronavirus outbreaks. This adds up to more than 12 million Aussies living under stay-at-home orders as concern grows over the country's Covid-19 situation.South Australia yesterday recorded its first community case after more than 200 days of not having any community transmission. The miner's four household contacts tested positive as well. SA Health workers are scrambling to determine the source of the infection and how many other community members were in contact with the person.While holding back on imposing...

A second nurse at Royal North Shore Hospital has tested positive to COVID-19. See omnystudio.com/listener for privacy information.

A second nurse at Royal North Shore Hospital has tested positive to COVID-19. See omnystudio.com/listener for privacy information.

He is a graduate of the UMDNJ- Robert Wood Johnson Medical School (Rutgers Medical School). He did his residency at the University Of Texas Medical School's Department of Anesthesiology and interventional Fellowship with world-renowned specialist, Professor Michael Cousins, at the Royal North Shore Hospital in Sydney, Australia. Dr. Grover also enjoys his work as a television medical correspondent with Fox news, CNN and has been featured on the Discovery Channel, NBC, ABC, CBS and PBS. In response to his work in Pain Management and humanitarian efforts, he was given a national award at the White House from President Clinton and First Lady Hillary Clinton. Our radio shows archives and programming include: A Different Perspective with Kevin Randle; Alien Cosmic Expo Lecture Series; Alien Worlds Radio Show; Connecting with Coincidence with Dr. Bernard Beitman, MD; Dick Tracy; Dimension X; Exploring Tomorrow Radio Show; Flash Gordon; Jet Jungle Radio Show; Journey Into Space; Know the Name with Sharon Lynn Wyeth; Lux Radio Theatre - Classic Old Time Radio; Mission Evolution with Gwilda Wiyaka; Paranormal StakeOut with Larry Lawson; Ray Bradbury - Tales Of The Bizarre; Sci Fi Radio Show; Seek Reality with Roberta Grimes; Space Patrol; Stairway to Heaven with Gwilda Wiyaka; The 'X' Zone Radio Show with Rob McConnell; and many other! That's The ‘X' Zone Broadcast Network Shows and Archives - https://www.spreaker.com/user/xzoneradiotv *** AND NOW *** The ‘X' Zone TV Channel on SimulTV - www.simultv.com The ‘X' Chronicles Newspaper - www.xchroniclesnewspaper.com

Surviving Massive Burns: Jamie Manning and the Royal North Shore Hospital team. In this panel discussion, we hear an incredible patient story from Jamie Manning and his wife, Karen Manning. In March 2014, Jamie was involved in a horrific car accident which resulted in catastrophic injuries and extreme burns to 40% of his body. Jamie and Karen reflect on their journey to recovery and their experience with the hospital system. They are joined on the panel by a number of the healthcare professionals who were involved with Jamie's recovery.  In this discussion, the team reflect on learnings for the future, such as the importance of continuity of care. Tune in to an unmissable podcast from #SMACC2019.  For more head to: codachange.org/podcasts

The Joint Action podcast was launched in April 2019 during the COVID-19 pandemic and since then, we have grown our listener base to an international audience. We aim to bring evidence based and up-to-date knowledge about osteoarthritis to our listeners by interviewing the world’s experts in osteoarthritis. On this very special episode of Joint Action, we will be chatting to David to learn more about his story and also answer some of our listener questions. Professor Hunter is a rheumatology clinician researcher whose main research focus has been clinical and translational research in osteoarthritis. He is the Florance and Cope Chair of Rheumatology and Professor of Medicine at University of Sydney and the Royal North Shore Hospital. He is ranked as the world’s leading expert in osteoarthritis on Expertscape.com since 2014. Dr Hunter has over 500 peer reviewed publications in international journals, numerous book chapters, is the section editor for UpToDate Osteoarthritis and has co-authored a number of books, including books on self-management strategies for the lay public.RESOURCESInstitute of Bone and Joint Research Facebook pageJoint Action webpageCONNECT WITH USTwitter: @ProfDavidHunter @jointactionorg @vickyduongEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! If you have any questions, feel free to send us an email :) See acast.com/privacy for privacy and opt-out information.

The former Liberal staffer at the centre of allegations he assaulted Brittany Higgins and two other women has reportedly checked in to a private rehabilitation clinic, days after staying overnight in hospital and being stood down from his his job at a large corporation.It is understood he admitted himself to Royal North Shore Hospital in Sydney, seeking psychiatric care, shortly after the story broke last week.According to a report in the Sydney Morning Herald, former employers, colleagues, and university peers of the man, who has worked for a large corporation in Sydney since July 2020, claim he was an ambitious, self-important and “a real lad’s lad”, but that they were shocked by the accusations.A spokesman for the large corporation where he worked confirmed the man had been stood down, but would not confirm whether the company was asking its staff if they had experienced any misconduct.Ms Higgins told news.com.au the man was a “rising star” within the Liberal Party at the time of her alleged assault. He had been working for the Coalition for four years.However, students who studied with him at the Australian National University in 2016 said he had more confidence in his own skills than was warranted.“He was not a nice person overall, he didn’t work hard, he just wanted … all the praise for doing pretty much nothing. A real lad’s lad,” the Sydney Morning Herald reported one former student as saying.“He just thought more of himself than any of us did, he did literally nothing, just showed up for the drinking, the socialising.”He was dismissed over the “security breach” in the days after the alleged incident involving Ms Higgins.Meanwhile, Ms Higgins’ partner has resigned from his job. David Sharaz told news.com.au his job in Canberra, where he handled federal government clients for a media analytics company, is no longer tenable. He worked for Sky News and SBS before joining a media monitoring company this year.Mr Sharaz said his bosses had been supportive and given him time off last week to support Ms Higgins but he accepted that his job, which involves seeking government contracts, was no longer tenable.Mr Sharaz said his decision to resign had “no regrets” for standing by Ms Higgins and supporting her fight for justice. “I have absolutely no regrets in choosing to support my partner and I will continue to do so,’’ he told news.com.au.“The standard you walk past is the standard you accept. Being supportive is the least that I - or any other partner of a victim-survivor can do.“Brittany - and many others deserve better.”Last week, news.com.au broke the story about Ms Higgins’ alleged sexual assault at Parliament House, after a night drinking with colleagues in March 2019.It is understood that Ms Higgins intends to make a formal statement to police on Wednesday afternoon to reactivate an investigation into her allegations of rape.In the days since the story broke, three other women – including another former Liberal Party staffer and a former Liberal Party volunteer – have come forward, claiming that they too either received unwelcome advances or were assaulted by the same man, a colleague who was regarded as a “rising star” in the party.One of those women said she had met the man during the 2016 federal election campaign and they had stayed in touch.She claims they caught up for dinner in 2020, where the former staffer bought her several drinks. She said they then went back to her home where she claimed she was raped.Another woman, a Liberal Party volunteer, also alleges she was assaulted after a night of drinking with the man, who offered to “look after her” at his nearby hotel.She claimed when she woke up, her blouse buttons were undone and her jeans pushed down and the man was “lying on top of her”.The former staffer has not been charged over any of the alleged incidents.A fourth woman has also claimed she was the target of inappropriate advances by the same man.The woman made a report at a...

As Valentine's Day approaches there is a lot of pressure to focus on pleasing someone else, but The Quicky is reclaiming this special day by writing a love letter to our vaginas. There's a lot we don't, but should know about the lovely lady downstairs, so sit back, relax and pick up a hand mirror to explore and appreciate her in all her glory, and learn how to recognise when something isn't right. Subscribe to The Quicky at... https://mamamia.com.au/the-quicky/ CREDITS  Host/Producer: Claire Murphy Executive Producer: Siobhán Moran-McFarlane Audio Producer: Ian Camilleri Guests: Professor Gayle Fischer - Academic Dermatologist at the University of Sydney, Head of the Vulval Dermatology Clinic at the Royal North Shore Hospital, and Head of Research at The Skin Hospital in Darlinghurst. CONTACT US Got a topic you'd like us to cover? Send us an email at thequicky@mamamia.com.au Mamamia acknowledges the Traditional Owners of the Land we have recorded this podcast on, the Gadigal people of the Eora Nation. We pay our respects to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander cultures. See omnystudio.com/listener for privacy information.

Two inspiring and innovative educationalists, Dr Roger Harris and Dr Oliver Flower, are featured in this episode. Both of these Sydney intensivists are the force behind the recently created educational initiative named Coda, having previously been two members of the successful triumvirate who set up SMACC (Social Media and Critical Care). To my mind Oliver (or Oli) and Roger have led an educational revolution by utilising speakers with high level presentation skills and encouraging community engagement, through a blend of real life events, internet technology and social media, to bring us the type of innovative and entertaining educational platform we haven’t previously seen in intensive or critical care. Dr Roger Harris is a senior staff specialist in the ICU at the Royal North Shore hospital and the Sydney Adventist hospital. He is dual qualified in Emergency Medicine and Intensive Care. He is passionate about education, his five children and especially his wife Georgie. He’s on Twitter @RogerRdharris where his bio states he is “privileged to care for the critically ill.” Dr Oli Flower is also an intensivist at the Royal North Shore Hospital in Sydney. He’s steered the creative side of SMACC & Coda, from the graphic design elements to the style, marketing, website and social platform strategies. He has an interest in neurocritical care and is on Twitter @oliflower where his bio states he is a “believer in the power of the big medical community”. We recorded this in February 2020; just before the COVID-19 pandemic scuppered Oli and Roger’s plans to release nearly 4000 tickets to the inaugural large-scale Coda event. Coda is aimed to be more like a festival than a conference and is not only for critical care practitioners but for a wider healthcare audience. The overall goal of Coda is to cover vital broader healthcare subject themes and to assist the assembled community to take meaningful actions as a result of what is discussed, the climate emergency being one of the first of these. When Coda was one of the earlier healthcare conferences to be postponed in the pandemic, I also held this podcast back until there could be firmer plans about any live Coda events. A meeting named Coda Zero Live has now been announced for 16-18 February 2021. This is an event in Sydney with both a live and a virtual audience. It now seemed appropriate to release this episode to help you know about Coda and to encourage you to attend or tune in to Coda Zero Live. This interview is well worth listening to as, despite no mention of COVID-19, you’ll hear: The career backgrounds of Oli and Roger Roger's humility in training in a second speciality in the same hospital Both of their views on the mature culture and flattened hierarchy in their ICU at Royal North Shore Hospital Perspectives on gender equity as well as diversity and inclusion in an Intensive Care department The story behind the educational initiatives of SMACC and Coda The marginalisation of non-technical topics they noticed in most scientific meetings The growing appetite they were observing for these same topics The value of delegate feedback in directing educational initiatives How SMACC developed such an engaged community The vision for Coda including its initial themes of education, ethics, earth and cure The plans for tackling the climate emergency as a healthcare practitioner community Discussion about how a plant-rich diet is beneficial for both environmental and personal health What Oli and Roger have learnt from all these educational pursuits to help them at the bedside How they both stay balanced Some tips for less experienced clinicians   Please enjoy listening to Roger Harris & Oli Flower.   Andrew Davies   --------------------   About the Mastering Intensive Care podcast: The podcast aims to inspire and empower you, through conversations about the human side of Intensive Care, to bring your best self to the Intensive Care bedside, with a focus on compassion, collaboration and personal wellbeing.   --------------------   Links related to Roger Harris and Oli Flower Roger Harris Roger Harris on Twitter @RogerRdharris Oli Flower Oli Flower on Twitter @OliFlower Intensive Care Unit at Royal North Shore Hospital Coda Coda on Twitter Coda Zero Live Event - 16-18 February 2021 Intensive Care Network Intensive Care Network podcasts   Links to other resources (in order of mentioning) Chris Nickson SMACC Coda Coda Zero Live Queen Square Sydney HEMS Staff at Royal North Shore Hospital ICU Australasian Trauma Society Australasian College of Emergency Medicine College of Intensive Care Medicine SMACC Berlin Final Day Program Martin Bromiley Life In The Fast Lane Blog Intensive Care Network Simon Carley St Emlyn’s Scott Weingart EMCrit Haney Mallemat Ken Milne SMACC Conference History ANZICS SCCM Rob MacSweeney Critical Care Reviews Conference Jesse Spurr Mary Freer New England Journal of Medicine John Hinds Coda Zero Episode 1: Cure - Pandemic Sepsis Coda Zero Episode 2: Ethics - Gender Video Coda Zero Episode 3: Educate - Communicating in the era of big data, AI and the “infodemic” Coda Zero Episode 4: Earth - A safe and healthy pandemic recovery Coda Zero Live Event - 16-18 February 2021 Safe Airway Society   Links related to Mastering Intensive Care podcast Mastering Intensive Care podcast Mastering Intensive Care podcast - Episode 21 with Martin Bromiley Mastering Intensive Care podcast - Episode 28 with Simon Finfer Mastering Intensive Care podcast - Episode 45 with Scott Weingart Mastering Intensive Care page on Facebook Mastering Intensive Care at Life In The Fast Lane Andrew Davies on Twitter: @andrewdavies66 Andrew Davies on Instagram: @andrewdavies66 Andrew Davies on LinkedIn Email Andrew Davies Audio Producer Chris Burke Burke Sound & Media

In this episode:  It’s a common problem but still one that causes confusion If PPIs fail then refer Make sure you investigate atypical symptoms Host: Dr David Lim | Total time: 20 mins Guests: Dr May Wong, Gastroenterologist; Staff Specialist, Royal North Shore Hospital.    Register for our upcoming FREE WEBCAST! Tuesday 1 December 2020 | 7:00pm-9:00pm AEDT Click here to register now! See omnystudio.com/listener for privacy information.

In this episode:  While diagnosis can be difficult, exclude other pathology and stay alert to GORD mimickers Most can be managed in GP Team approach including psychologist and dietitian can be very helpful   Host: Dr David Lim | Total time: 31 mins Guests: Dr May Wong, Gastroenterologist; Staff Specialist, Royal North Shore Hospital.    Register for our upcoming FREE WEBCAST! Tuesday 1 December 2020 | 7:00pm-9:00pm AEDT Click here to register now! See omnystudio.com/listener for privacy information.

International composer Ken Davis has performed at the Sydney Opera House and is known as the first and most successful new age music composer, a major pioneer in ambient music and now creates music for relaxation and healing. In this episode we discuss how music and the mind body connection can help to heal us from trauma, anxiety and stress. As a world famous artist, Ken has collaborated with medical facilities and contributed to the design and ambience of the Healing Rooms at the Royal North Shore Hospital in Sydney, Australia. We discuss how music can be used as an effective therapy and outlet for emotions as well as having many physiological benefits. Ken demonstrates with one of his beautiful crystal bowls the power of this ancient vibrational music and its cognitive stimulus. To find out more about Ken Davis and his music, you can visit his website www.kendavismusic.com To find out more about Dr. Amanda Ferguson, you can visit her website at www.dramandaferguson.com.au Or connect with her on Facebook or LinkedIn

The community has raised over $76,000 to support the medical costs for the treatment of Johny Sahota, a young Indian migrant admitted at the Royal North Shore Hospital in Sydney. The family was already under immense financial stress due to his wife’s ongoing illness. - ਸਿਡਨੀ ਦੇ ਰਾਇਲ ਨੌਰਥ ਸ਼ੋਰ ਹਸਪਤਾਲ ਵਿੱਚ ਰੀੜ੍ਹ ਦੀ ਹੱਡੀ ਦੀ ਗੰਭੀਰ ਸੱਟ ਪਿੱਛੋਂ ਜ਼ੇਰੇ-ਇਲਾਜ ਪੰਜਾਬੀ ਨੌਜਵਾਨ ਦੇ ਮੈਡੀਕਲ ਖਰਚੇ ਲਈ ਭਾਈਚਾਰੇ ਵੱਲੋਂ 1 ਲੱਖ ਡਾਲਰ ਤੋਂ ਵੀ ਵੱਧ ਦੇ ਫੰਡਜ਼ ਇਕੱਠੇ ਕੀਤੇ ਗਏ ਹਨ। ਜੋਨੀ ਸਹੋਤਾ ਨੇ ਦੱਸਿਆ ਕਿ ਉਨ੍ਹਾਂ ਦੀ ਪਤਨੀ ਜੋ ਇੱਕ ਗੰਭੀਰ ਆਟੋ-ਇਮਿਊਨ ਬਿਮਾਰੀ ਤੋਂ ਪੀੜ੍ਹਤ ਹੈ, ਕਰਕੇ ਪਹਿਲਾਂ ਹੀ ਉਨ੍ਹਾਂ ਦਾ ਪਰਿਵਾਰ ਭਾਰੀ ਆਰਥਿਕ ਤਣਾਅ ਵਿੱਚੋਂ ਗੁਜ਼ਰ ਰਿਹਾ ਸੀ।

Multiple sclerosis, or MS, is a topic we've covered in the past. But, everyone's experience with the condition is unique. In our next two episodes, we hear from Astrid, an MS advocate who has been living with the condition for over six years. In this episode, we hear her diagnosis story, as she provides some helpful advice she's learned over the years. We also hear from Dr. John Parratt, a neurologist at Royal North Shore Hospital in Sydney, Australia, who provides a clinical perspective and advice from his years treating MS patients. This episode is kindly supported by MS Australia and is sponsored by Roche Australia (Sydney). Material number EC-AU-9369, prepared Apr2020. Episode References:  MS Australia. Understanding Multiple Sclerosis – An Introductory Guide. Available at: https://www.msaustralia.org.au/publications/understanding-ms-introductory-guide Chwastiak LA, Ehde DM. Psychiatric issues in multiple sclerosis. Psychiatr Clin North Am. 2007;30(4):803–817. 

Rosie Venman is a clinical Dietitian working at Royal North Shore Hospital. Rosie received her Bachelor’s degree in Food Science and Human Nutrition from the University of Newcastle and a Masters in Nutrition and Dietetics from Sydney University. At Royal North Shore Hospital she has been working as the Osteoarthritis Chronic Care Program Dietitian for the last 4 years and has a keen interest in improving weight loss outcomes for this patient group.On this episode we discuss: how to lose weight and keep it off, options of diets for people with osteoarthritis, dietary strategies and much more.ResourcesMyFitnessPalEasy Diet Diary Calorie KingRegister for the Mine the Gap online workshop here. See acast.com/privacy for privacy and opt-out information.

In this Episode: A substantial proportion of those who have had COVID-19, experience health issues many weeks and months after the acute infection As part of the clinical approach, ask about level of energy and general function, “brain fog”…mental clarity and general pain Mental health, shortness of breath are important issues to monitor for It will be a multidisciplinary challenge and specialist opinion will often be needed, but GPs will be central players in this process Host: Dr David Lim, GP Guest: Dr Jim Newcombe, Infectious Diseases Physician, Clinical Microbiologist; Royal North Shore Hospital, Douglass Hanly Moir Pathology Total time: 38 mins   FREE Webcast! Tuesday, 25 August 2020 7:00pm-9:00pm AEST Register Now!   See omnystudio.com/listener for privacy information.

Dr. Todd McMullen is a scientist and endocrine surgeon at the University of Alberta in Edmonton, Alberta. In this episode we talk to Dr. McMullen about a topic that is sometimes a pain in the neck for trainees: thyroid nodules. Dr. McMullen gives us his approach to nodules, how he works them up, a brief overview of how he does his thyroidectomies, and post op calcium management. We hope you enjoy! Dr. Todd McMullen is a fellowship trained endocrine surgeon with specialized training in thyroid ultrasound techniques.He received his PhD in Biochemistry from the University of Alberta, then completed a Medical Research Council of Canada Post-Doctoral Fellowship in the Department of Physiology at the University of Virginia in Charlottesville, Virginia. Having received his PhD and additional training in Physiology, Dr. McMullen went on to complete medical school at the University of Toronto and a residency in General Surgery at the University of Alberta. He further specialized in Endocrine Surgery at the Royal North Shore Hospital in Sydney, Australia, where he finished a TS Reeve Fellowship in Endocrine Surgery. Since that time, Dr. McMullen has been an active member of the University of Alberta staff as part of the Faculty of Medicine and Dentistry, where he now holds positions in Surgery and Oncology (Division of General Surgery), an Adjunct appointment in the Division of Endocrinology (Department of Medicine) and also serves as the Director of the Division of Surgical Oncology (Department of Oncology) based at the Cross Cancer Institute. In this episode we get Dr. McMullen's approach to thyroid nodules, thyroidectomies and post-op management. Links: 1. TIRADS score: https://radiopaedia.org/articles/acr-thyroid-imaging-reporting-and-data-system-acr-ti-rads 2. South Korea's Thyroid-Cancer "Epidemic"--Turning the Tide. https://pubmed.ncbi.nlm.nih.gov/26650173/ 3. The 2017 Bethesda System for Reporting Thyroid Cytopathology. https://pubmed.ncbi.nlm.nih.gov/29091573/ 4. Minimally invasive thyroid surgery for single nodules: an evidence-based review of the lateral mini-incision technique.

Peter is Professor and Head of Pharmacology in the School of Medicine, University of Notre Dame, Sydney and an Honorary Professor in the Discipline of Pharmacology, Sydney Medical School, University of Sydney and Northern Clinical School, Royal North Shore Hospital, Sydney. He is also the President of the New South Wales Branch of the Pharmaceutical Society of Australia. At present he works in community pharmacy, and teaches Clinical Pharmacology to Medical, Nursing and Pharmacy students.He is Chairperson of the Editorial Board of the Australian Journal of Pharmacy, a former Dean and President of the Australian College of Pharmacy Practice and a former Chairperson of the Pharmaceutical Society of New South Wales.He is a Fellow of the Pharmaceutical Society of Australia, a Fellow of the Australian College of Pharmacy Practice and a recipient of the University of Sydney Pharmacy Practice Foundation Medal of Excellence for Pharmacy Practice.He has previously worked in hospital pharmacy and held both medical and marketing positions within the pharmaceutical industry.ResourcesMedsCheck from pharmacist if you are on 5 or more medicinesHome Medication Review from GP See acast.com/privacy for privacy and opt-out information.

Matthew Williams is a physiotherapist with over 15 years of experience and has been the musculoskeletal coordinator of the Osteoarthritis Chronic Care Program at the Royal North Shore Hospital for the last 8 years. He has worked in a variety of healthcare settings in public and private industry, both nationally and in the United Kingdom, and Subcontinent. His passion lies in improving the lives of individuals with osteoarthritis through tailored exercise programs and coordinating care utilising non-surgical evidenced based treatment options. Most recently, Matthew has been a respresentative for the Asia-Pacific region in developing a package of interventions for the management of osteoarthritis for the World Health Organisation to be utilised globally.On this episode we discuss: practical tips for exercising with osteoarthritis, what type of exercise is appropriate and how much to do and much more.Resources mentioned on this episode:Choose PhysioMy Joint PainArthritis AustraliaArthritis NSWBeyond BlueMindSpot Clinic See acast.com/privacy for privacy and opt-out information.

Kristin flies solo this week to talk to Dr Lisa Kouladjian O'Donnell, a consultant pharmacist and postdoctoral research associate affiliated with the NHMRC Cognitive Decline Partnership Centre, The University of Sydney, and the Kolling Institute, Royal North Shore Hospital, NSW. Kristin and Lisa discuss: definitions of polypharmacy and deprescribing drivers of polypharmacy at-risk populations a collaborative approach to deprescribing the Drug Burden Index (DBI) calculator You can read more about Lisa’s work here. The Goal-directed Medication review Electronic Decision Support System (G-MEDSS) is here.

In this Healthed interview, Prof Rod Baber, Clinical Professor of Obstetrics and Gynaecology at Sydney Medical School, and Head of the Menopause and Menstrual Disorders clinic at Royal North Shore Hospital, discusses the management of menopausal symptoms, as well as the different treatments and their risks with regard to breast cancer, with GP and RACGP President Dr Harry Nespolon.

On December 9 2019, 47 tourists and guides were visiting the White Island volcano in New Zealand when it erupted.  20 people were killed, and 26 were injured, and many Australians were among those numbers.  Many of the injured suffered serious burns, and in the days after the eruption 13 Australians were flown to hospitals in Sydney and Melbourne for treatment.  Six patients ended up in the Burns Unit at Royal North Shore Hospital in Sydney, a statewide burns service that was also treating burns victims from the bushfires. On this week’s Please Explain Feature episode, Sydney Morning Herald Health Reporter, Rachel Clun will take you through the burns unit and you’ll get a glimpse of just what it takes to treat serious burns after a natural disaster

In this episode, we talk to Dr Mike Freelander MP, Federal Member for Macarthur and Government Whip, about engaging the Australian voters in the political discourse. Topics covered include: - How a ‘boomer' politician can understand the needs of young voters - What life was like for young Australians in the 1970s - The biggest struggles for young Australians - What Australians are facing with the current housing and rental market - How the Opposition can influence policy change and development in Australia - The important role of committees in bipartisan policy recommendations - How working as a doctor led to a career in politics - The impact of politics on people's health - The growing trend towards conservative politics globally - How technology has changed our society - The need to provide more political education in schools - How young people can engage in the political agenda - The benefits of having political discussions at the dinner table - The slightly misunderstood nature of Federal Parliament in Australia - The benefits of school trips to Canberra - Whether or not the voting age should be lowered - The challenges currently facing constituents in the Macarthur electorate - The lack of future planning in Australia - How we deal with the growing population of Australia, including through immigration - The rhetoric around climate change About Dr Freelander: Dr Mike Freelander has been a paediatrician in Campbelltown for 36 years and has dedicated his life's work to make sure our kids get the best start in life. Mike trained as a paediatrician at the Royal Alexandra Hospital for Children in Camperdown after completing his residency at the Royal North Shore Hospital. In 1984, Mike and his wife Sharon moved to the Macarthur Region where they raised their six children. At this time Mike commenced work at Campbelltown Hospital where he took on the role as Head of Paediatrics from 1986 to 2013. Mike set up practices in Campbelltown and Camden because he saw that the growing needs of the region were not being met. Despite his workload as a paediatrician Mike still finds time to give back to his profession, teaching the next generation of doctors as a lecturer at Western Sydney University. His hard work and dedication to the region has earnt him the respect of local families and residents. In his 36 years as a paediatrician in the Macarthur region, Mike has seen over 200,000 patients. Mike has increasingly seen his patients and their families face issues of access; access to healthcare, access to work, access to housing and access to education. It is these issues that drove Mike to run for the Federal seat of Macarthur.  Mike is here to try and make life better for the children he has cared for and their families.

In today’s episode, I interview Trishna. Trishna gave birth to her first baby under the care of midwives through the Royal North Shore Hospital. As an avid gym enthusiast, Trishna stayed very active throughout her pregnancy and labour. She continued her F45 workouts, took pregnancy yoga classes and reformer pilates. Together with her partner Trishna took a  Calmbirth course to help equip her for the low intervention water birth she hoped for. To hear her full story tune into this week’s episode.

Listen as author, Dr. Paul Atkinson, discusses the use of point-of-care ultrasound in Emergency Medicine and Resuscitation. Dr. Paul Atkinson is Professor in Emergency Medicine at Dalhousie University and Saint John Regional Hospital, New Brunswick, Canada. He is the current chair of the provincial Emergency Medicine research committee. Paul is also deputy editor of CJEM, Chief Medical Officer at WorkSafeNB, and is currently VP for ultrasound research for the International Federation for Emergency Medicine (IFEM). He is co-director of the Emergency Critical Care Ultrasound (ECCU) course. His international training included Royal North Shore Hospital in Sydney, Australia, and Cambridge University Hospitals in the UK. He is the principal investigator and chair of the SHoC ultrasound research network. He has over 80 peer-reviewed publications, as well as being the lead editor on two textbooks, Emergency Medicine an Illustrated Colour Text, 2010; and Point of Care Ultrasound in Emergency Medicine and Resuscitation, 2019. Awards include the inaugural “Best in Class” undergraduate teaching award from Dalhousie University in 2012, and the national Grant Innes Award for Emergency Medicine research in 2014, and the Ian Stiell Researcher of the Year Award from the Canadian Association of Emergency Physicians, 2019. Current research interests include PoCUS in critical illness, occupational stress injury, medical education, trauma systems, and prevention, as well as quality in medicine. Paul enjoys cycling and hiking in the wide-open spaces of New Brunswick.

Professor David Hunter is a rheumatology clinician-researcher whose main research focus has been clinical and translational research in osteoarthritis (OA). He is the Florance and Cope Chair of Rheumatology and Professor of Medicine at the University of Sydney and the Royal North Shore Hospital and Consultant Rheumatologist at North Sydney Orthopaedic and Sports Medicine Centre. He is ranked as the world's leading expert in osteoarthritis on Expertscape.com since 2014. He is on the editorial board for Arthritis and Rheumatology, Osteoarthritis and Cartilage, Arthritis Care and Research and part of the review committee for OA for the American College of Rheumatology, EULAR and OARSI scientific meetings. Dr Hunter has over 400 peer-reviewed publications in international journals, numerous book chapters, is the section editor for UpToDate Osteoarthritis and has co-authored a number of books.  He is also Co-Chair of the recent RACGP Osteoarthritis guidelines.  This was a thoroughly enjoyable and informative discussion around osteoarthritis pathophysiology, imaging, prevention and treatment.  There was a bit of mic rustling when David speaks but this stops at ~11:25mins (to be exact!). Resources mentioned: Patient program - https://www.myjointpain.org.au/ RACGP guidelines = 2018 Royal Australian College of GPs Guidelines: https://www.racgp.org.au/your-practice/guidelines/musculoskeletal/hipandkneeosteoarthritis/ Warm up programs to prevent injuries: PEP: https://www.aclstudygroup.com/pdf/pep-program.pdf FIFA 11 training: Shorter version - https://www.tmphysio.com/wp-content/uploads/2017/08/FIFA-11-_Poster_EN_Druck_2015.compressed.pdf Longer version - https://www.kort.com/uploadedFiles/KORT/Content/Services/Sports_Medicine/Concussion_Management/FIFA-the-11-Booklet.pdf   Other resources: Some published references: Clinical algorithms to aid osteoarthritis guideline dissemination. Osteoarthritis Cartilage. 2016 Sep;24(9):1487-99. Osteoarthritis: Models for appropriate care across the disease continuum. Best Pract Res Clin Rheumatol. 2016 Jun;30(3):503-535. Therapy: Are you managing osteoarthritis appropriately? Nat Rev Rheumatol. 2017 Dec;13(12):703-704. Lower extremity osteoarthritis: optimising musculoskeletal health is a growing global concern: a narrative review. Br J Sports Med. 2018 Jul 20.   Multimedia options: Annual Florey Public Lecture: https://www.youtube.com/watch?v=vY__ApcQOOc Article author Professor David Hunterdiscussed appropriate osteoarthritis management. Short video:https://vimeo.com/108976519 Podcast from Radio National Health Report: Everything you ever wanted to know about osteoarthritis:https://www.abc.net.au/radionational/programs/healthreport/everything-you-ever-wanted-to-know-about-osteoarthritis/8664218   An online electronic educations module for RACGP for CPD points: https://www.racgp.org.au/education/courses/activitylist/activity/?id=54640&q=keywords%3dosteoarthritis%26triennium%3d17-19   As always – rating this podcast 5 stars and leaving a review in iTunes is great help. Enjoy Friends  

Dr. Oliver Flower is a British Intensive Care Consultant based at the Royal North Shore Hospital in Sydney, Australia. He is one of the creators of the SMACC conference which has been a driving force for the social media-driven revolution in medical education. He is passionate about Neurocritical Care, graphic design and Mixed Martial Arts (he practices jiu jitsu and has worked as a cage-side doctor). He also runs the educational and networking site Intensive Care Network. Accompanying blog post at pondermed.com

Dr Carolyn Lam:                Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. I'm Dr Carolyn Lam, associate editor from the National Heart Center and Duke National University of Singapore.                                                 Does measuring baseline BNP add prognostic information in patients undergoing revascularization for left main coronary artery disease? Well, to find out the answers, you have to stay tuned and listen up for our feature discussion coming right up, after these summaries.                                                 The first original paper this week reports a new role for bone morphogenetic protein 9, or BMP9, as an endogenous inhibitor of cardiac fibrosis. Now, we are familiar with transforming growth factor beta-one, or TGF-β1, as a promoter of cardiac fibrosis. TGF-β1 also activates counterregulatory pathways that serve to regulate TGF-β1 activity in heart failure. BMP9 is a member of the TGFβ family of cytokines and signals via the downstream effector protein Smad1.                                                 In the current paper from first author Dr Morine, corresponding author Dr Kapur, from Tufts Medical Center in Boston, and their colleagues. The authors examined BMP9 expression and signaling in human cardiac fibroblasts and human subjects with heart failure. They utilized the thoracic aortic constriction–induced model of heart failure to evaluate the functional effect of BMP9 signaling on cardiac remodeling. The authors’ results identified a novel functional role for BMP9 as an endogenous inhibitor of cardiac fibrosis due to LV pressure overload. They further showed that treatment with either recombinant BMP9 or inhibiting a high affinity receptor for BMP9 known as endoglin promoted BMP9 activity and limited cardiac fibrosis in heart failure. Thus, this provides a potential novel therapeutic approach for patients with heart failure.                                                 The next paper shows that endothelial C-type natriuretic peptide, or CNP, regulates microcirculatory flow and blood pressure. First author, Dr Špiranec, corresponding author Dr Kuhn, and colleagues from University of Würzburg in Germany analyzed whether vasodilating response to CNP changed along the vascular tree. In other words, whether the guanylyl cyclase–B receptor was expressed in microvascular types of cells. The authors used novel gene-modified mouse models to show that guanylyl cyclase–B cyclic GNP signaling in parasites diminished microcirculatory resistance and arterial blood pressure. In contrast, endothelial, or macrovascular smooth muscle cell guanylyl cyclase–B signaling was not involved. This indicated that CNP participated in the local cross talk between endothelial cells and parasites, thus playing an important role in the maintenance of normal microvascular resistance and blood pressure. Thus, pharmacological augmentation of endogenous CNP signaling in parasites may provide a useful therapeutic tool to combat increased vascular resistance and hypertension.                                                 Has the rapid and exponential growth in transcatheter aortic valve replacement, or TAVR, demand overwhelmed capacity, thus translating to inadequate access and prolonged wait times? Well, the next paper provides some answers. First author, Dr Elbaz-Greener, corresponding author Dr Wijeysundera, from University of Toronto, evaluated temporal transient TAVR wait times and the associated clinical consequences in their population-based study of all TAVR referrals from April 2010 to March 2016 in Ontario, Canada. Their study cohort included 4,461 referrals, of which 50% led to a TAVR, 39% were off-listed for other reasons, and 11% remained on the wait list at the conclusions of the study.                                                 For patients who underwent a TAVR, the estimated median wait time in the post reimbursement period stabilized at 80 days and has remained unchanged. The cumulative probability at 80 days of wait-list mortality was 2% and of heart failure hospitalization, 12%, with an increase in events with increased wait times. Thus, post reimbursement wait time has remained unchanged for patients undergoing a TAVR procedure, suggesting that the increase in capacity has kept pace with the increase in demand. The current wait time of almost 3 months is associated with important morbidity and mortality, suggesting a need for greater capacity and access.                                                 The final paper shows that patients with type 2 diabetes and a history of heart failure are particularly likely to benefit from treatment with the SGLT2 inhibitor canagliflozin. First author, Dr Rådholm, corresponding author Dr Figtree, from Royal North Shore Hospital in Australia, and colleagues, studied more than 10,000 participants with type 2 diabetes and high cardiovascular risk in the CANVAS Program who were randomly assigned to canagliflozin or placebo and followed for a mean of 188 weeks. Participants with a history of heart failure at baseline constituted 14.4% of the study population and were more frequently women, white, and hypertensive, with a history of prior cardiovascular disease. The benefit of canagliflozin on cardiovascular death and hospitalized heart failure was greater in patients with a prior history of heart failure compared to those without heart failure at baseline with a p for interaction of 0.02. The effects of canagliflozin compared with placebo on other cardiovascular outcomes and key safety outcomes were similar in patients with and without heart failure at baseline. Effects were apparent across a broad range of participant subgroups, including those using established treatments for the prevention of heart failure, such as renin-angiotensin-aldosterone system inhibitors, diuretics, and beta-blockers. Thus, patients with type 2 diabetes and a history of heart failure may be particularly likely to benefit from treatment with canagliflozin. The beneficial effects of canagliflozin on heart failure outcomes unlikely to be accrued on top of other therapies for heart failure management.                                                 And that brings us to the end of this week's summaries, now for our feature discussion.                                                 In patients with left main coronary artery disease who are undergoing revascularization, could BNP assessment be that precision medicine tool to aid us in our clinical decision making? Well, I am just so excited to discuss this very topic with the corresponding author for this feature paper, Dr Gregg Stone from Columbia University Medical Center, as well as our associate editor and editorialist for this paper, Dr Torbjørn Omland from University of Oslo.                                                 Gregg, it was a super smart idea to look at circulating BNP and how this may associate with outcomes, as well as therapies in the EXCEL trial. Please tell us what inspired you to do this and please tell us what you found. Dr Gregg Stone:                As everybody knows, BNP has been identified as an important prognostic factor in patients with heart failure and ischemic heart disease. It correlates with both cardiovascular and noncardiovascular mortality. Patients with left main disease are among the highest-risk patients that either interventional cardiologists or cardiac surgeons treat because of the amount of myocardium at risk, they often present in heart failure, and even if they're not in overt heart failure, they can be prone to large severe left ventricular dysfunction. So first we wanted to establish the prognostic utility of BNP in this patient population and then we were interested to see if it might have a role in helping differentiate which patients might have a better prognosis with either PCI or coronary artery bypass graft surgery.                                                 EXCEL is the largest trial to date of left main PCI versus CABG in a randomized format with 1905 enrolled patients. And overall, we found that PCI and CABG had similar rates of deaths, large myocardial infarction, or stroke in 3 years. But of course, there are high risk-patients and low-risk patients buried within those overall aggregate outcomes, and BNP was an important prognostic predictor of overall mortality in the trial. Both cardiovascular and noncardiovascular, but not of any other ischemic end points interestingly. Not myocardial infarction, stent thrombosis, graft occlusion, bleeding, revascularization. But definitely, mortality. Even independent of left ventricular ejection fraction and heart failure status.                                                 Now, when we looked at the outcomes of PCI versus bypass surgery, we actually found a very powerful interaction, such that at relatively lower BNP levels, patients who underwent PCI had a better prognosis and tended to have lower mortality. Where patients with high baseline BNP levels tended to have a better prognosis after surgery. Dr Carolyn Lam:                You know, Torbjørn, I love your editorial where you contextualize these findings so nicely. Could you do that for us now? Dr Torbjørn Omland:      First, I would like to congratulate Gregg and his team with this very interesting and very well-done study, and I think Circulation is very fortunate to be able to publish papers like this. We have known for quite a long time that BNP is a strong prognostic indicator across the spectrum of cardiovascular diseases and it seems to be particularly strongly associated with risk of heart failure events, cardiac arrhythmias, and risk of death. And, as shown in the EXCEL trial, the association with left ventricular ejection fraction is actually quite weak, and also the association with ischemic events. So, these findings fit very well with previous observations. The really novel and intriguing finding of this study is the very strong interaction between procedural BNP levels and the effect of the randomized therapies and, as you alluded to, all the investigators have tried to look at this in other more low-risk populations like in the LIPID trial but actually failed to find any significant interaction. It's really a novel and important finding. Dr Carolyn Lam:                That's true. Does it bring up the question are the natriuretic peptides just a better EF measurement? You mentioned that there was a correlation, what do you think, Gregg? Dr Torbjørn Stone:          Well, you know, there was a weak correlation between BNP and ejection fraction and history of heart failure but the prognostic utility of BNP in this study and its ability to differentiate between the outcomes of PCI versus CABG in patients with low versus high BNP was actually strongly independent of both congestive heart failure history and acute left ventricular ejection fraction. So, I think the BNP is giving a useful independent information. It's a strong reflector of both atrial and ventricular pressures and volume status, but it also reflects myocardial hypoxia, it may be involved in glycolysis and lipid peroxidation, and other mechanisms that we don't fully understand. There may be elements of diastolic dysfunction that we have not measured in this study and other mechanisms related to prognosis in these patients. So, while EXCEL was not set up to truly differentiate and delve deeply into the mechanisms of our observations, statistically these were strong associations that may prove clinically useful. Dr Carolyn Lam:                Right, I thought that was so intriguing as well, just the points that you brought up. First, let's just clarify for the audience that when you say low and high you were using a cutoff of 100. Dr Gregg Stone:                We did use a cutoff of 100 pg per mL as is common, but we also modeled BNP as a continuous measure. And actually the relationships were even stronger when modeled as a log hazard ratio continuous measure, both for mortality and for the primary end point. Dr Carolyn Lam:                Yeah, that's so cool. And Torbjørn, you talked about this in your editorial as well and I thought your point about the distributions of the ejection fraction versus the distribution of natriuretic peptide, that was very revealing, too. Would you like to explain your thoughts there? Dr Torbjørn Omland:      I found it very interesting that all of this is clearly a high-risk operation overall. More than 90% actually had what we regard a normal, or at least not a reduced ejection fraction. Whereas the distribution of BNP values were more widely distributed so that actually about 40% of participants had BNP levels above this ratio of 100 pg per mL. And that probably shows that in this population, BNP provides additional and independent information about the status of the myocardium that is not revealed by angiography or ejection fraction measurements. Dr Carolyn Lam:                That's true, and that's an important point because it added above the SYNTAX score, too, right Gregg? Dr Gregg Stone:                That's right, it was an independent predictor, and in fact the SYNTAX score and the severity of left main coronary disease did not vary, according to BNP levels, that is. High versus low BNP were equally distributed, not related to the anatomic extent and complexity of coronary artery disease. So, BNP is clearly reflecting a different state of the myocardium in a way that we can't measure with any other available test and that makes it quite a useful biomarker. Dr Carolyn Lam:                Exactly, so I think I'd like to wrap up with asking you both, you can already see what the potential clinical implications are, right? Which means that perhaps in a similar type of patient where there's equipoise of the revascularization method and has left main disease, maybe we should be using natriuretic peptides to guide our clinical decision making. What do you think are next steps before this is prime time? Dr Gregg Stone:                Well I can mention that when one makes a decision of the best revascularization modality for patients with extensive multi-vessel or left main coronary artery disease, there are many factors that go into that determination, both clinical, anatomic, is the patient a good candidate for one versus the other revascularization modality, what are the patient's preferences, what's the surgeon's or interventionalist's likelihood of being able to safely get the patient through the procedure and achieve complete revascularization.                                                 The SYNTAX score makes a difference, as does gender and age and kidney disease and COPD and ejection fraction and many other factors. So I think we can now add to that list BNP, although I will say this was a post-hoc study, we only had BNP available in approximately 60% of the patients, and while the outcomes were similar in the patients who we did not versus who we did have BNP, this has to be looked at as hypothesis-generating analysis, and we would love to also see this type of finding replicated in other large datasets. That being said, there are no other large left main or new multi-vessel disease trials that are planned right now to my knowledge, and I think given the breadth of this dataset and its size and scope, I do think that these findings are robust enough to use BNP as one of the clinical factors to consider in revascularization decisions. Dr Torbjørn Omland:      I actually agree with that and I think ideally, we would, of course, like to see external validation in another dataset and even retrospective randomized study comparing conventional versus BNP-guided strategy but that may not be realistically undertaken. So, I think these are clearly the best data we have and as clinicians need to integrate this in our overall evaluation in making this important decision. Dr Carolyn Lam:                Yeah, I mean Gregg, could I ask you, do you apply this clinically already? Dr Gregg Stone:                We have not been before this, although I believe we will now. I believe BNP should be a biomarker that we more routinely measure in patients with ischemic heart disease as well as those with overt congestive heart failure. And again, use as one of the factors of many when making revascularization decisions. And I think it's important to note also that the PCI patients tended to preferentially benefit, in fact with even lower mortality when BNP was lower. Where the surgical patients tended to benefit when BNP was higher. So, it's one factor, not the only factor, but I think it's one additional piece of the puzzle. Dr Carolyn Lam:                Yeah, I have to say too I mean, after reading this, after reading this awesome editorial, it's hard not to think I should be applying this clinically because it's going to be really hard and take a long time to prove this with more prospective data, for example. Although, external validation and other datasets may be better, this is the largest trial already to show this and show it so clearly with a significant interaction. I think that is striking to me.                                                 Torbjørn maybe I've put you on the spot with the last word, does this change your clinical practice? Dr Torbjørn Omland:      I agree with Gregg. This will be one of maybe several other factors but I think it's ready for being taken into account when making this sometimes very difficult decision. Dr Carolyn Lam:                Thank you so much Gregg and Torbjørn for joining me today. You've been listening to Circulation on the Run. Don't forget to tune in again next week.  

This week, we continue our suburb deep dive series on the Sydney Property Insider Podcast via our Suburb Spotlight! Today, we’re focussing on the leafy suburb of Naremburn. We discuss the history of the suburb, the demographics, upcoming development work, as well as the day-to-day specifics like local cafes, schools and transport   HERE’S WHAT YOU’LL LEARN FROM TODAY’S EPISODE:   The history of Naremburn; The original residents of the suburb; Tram and ferry access through the 1930’s; Entry level prices; Price data over past few years; How tightly held property in the suburb is; Transport links to the CBD; Public transport on the way for the area; Proximity to Royal North Shore Hospital; School zoning; Necessities in proximity; Why parking is particular important when looking to purchase in this area; And Dog friendly parks nearby   LINKS OR ARTICLES WE MENTIONED:   Naremburn Progress org edu.au School Finder   SPEAKERS IN TODAY’S EPISODE Michelle May - Sydney Buyers Agent Marcus Roberts - Mortgage Broker   ASK US ANYTHING!   Have a money question you want us to answer? ask@sydneypropertyinsider.com.au   FOLLOW US: Facebook   ENJOY THE SHOW? Don’t miss an episode, subscribe viaiTunes. If you like it, please leave a review! Or, find us on the podcast app of your choice, such as Spotify     Please note that any views or opinions presented in this podcast are solely those of the speakers, and do not necessarily represent those of any business. These views and opinions are general in nature, and do not take account of your personal objectives, financial situation and needs. Please consider whether it applies in your circumstances and seek professional advice wherever appropriate.

Does each bedside decision you make actually help your patient to feel, function or survive? Have you considered how frightening and intimidating the Intensive Care Unit environment is to your patients and their families? Do you feel empowered by the people you work with and the culture in your ICU?   Simon Finfer loves telling a tale. In this episode you’ll hear the story of the serendipitous and multi-national route Simon took to end up working for 25 years in one of Australia’s premiere Intensive Care Units. An Intensive Care Department where his colleagues and the culture they developed has fostered him to become one of Australia’s prominent intensive care researchers. You’ll also hear how he teaches his junior colleagues to question everything they do at the bedside to ensure their decisions truly help the patient. Simon is a Professorial Fellow in the Critical Care and Trauma Division at The George Institute for Global Health, a Senior Intensivist at Royal North Shore Hospital and Director of Intensive Care at the Sydney Adventist Hospital in Sydney, Australia. He is an Adjunct Professor at the University of New South Wales, a Clinical Professor at the University of Sydney and is a past-Chair of the Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Simon is a world leader in Sepsis and is an international expert in the design and conduct of large scale randomised controlled trials in Intensive Care. Simon has collaborated with me (and many others) through the ANZICS Clinical Trials Group, so we caught up at the Group’s recent 20th Annual Meeting on Clinical Trials in Intensive Care at Noosa Heads in Queensland. We had a fascinating conversation in which Simon talked about: His early career in London where he was simply working too hard The circuitous route he took to Royal North Shore Hospital in Sydney The magnificent people-oriented culture inspired by Malcolm Fisher His early collaboration with the George Institute for Global Health How showing you care is what matters most in an end of life discussion His thoughts on having family at the bedside for ward rounds How the golf course is the only place he doesn’t think about patients How moving to a property with animals has brought relaxation and peace The rekindling of his passion for motorbike riding Why he got a Twitter account and how social media is both a force for good and an echo chamber How it’s almost “too easy” to write a paper in modern times The unlikelihood of a magic bullet arriving anytime soon His advice to look after our selves, to embrace uncertainty and to maintain our humanity My genuine hope with this podcast is to inspire and empower you to bring your best self to work and to consider adopting some of the habits and behaviours my guests give their perspectives on, with the ultimate purpose of improving outcomes for all of our patients. Please help me to spread the message by simply emailing your colleagues, posting on social media or rating and reviewing the podcast. Feel free to leave a comment on the Facebook “mastering intensive care” page, on the LITFL episode page, on twitter using #masteringintensivecare, or by sending me an email at andrew@masteringintensivecare.com. Thanks for listening on the journey towards mastering intensive care. Andrew Davies   -------------------- Show notes (people, organisations, resources or links mentioned in the episode) 5th SG-ANZICS Asia Pacific Intensive Care Forum: www.sg-anzics.com ANZICS Clinical Trials Group: http://www.anzicsctg.org/ More information about Simon Finfer: https://www.georgeinstitute.org/people/simon-finfer Twitter handle for Simon Finfer: @icuresearch SAFE study: https://www.ncbi.nlm.nih.gov/pubmed/15163774 NICE-SUGAR study: https://www.ncbi.nlm.nih.gov/pubmed/19318384 SMACC: https://www.smacc.net.au/ Mastering Intensive Care podcast: http://masteringintensivecare.libsyn.com/ Mastering Intensive Care at Life In The Fast lane: https://lifeinthefastlane.com/litfl/mastering-intensive-care/ Email Andrew Davies: andrew@masteringintensivecare.com Twitter handle for Andrew Davies: @andrewdavies66

“ipsa scientia potestas est” This is FOAMed. Thus there are a lot of people that are nothing short of obsessed with airways. It’s as if humans were primarily a giant "Pass the Parcel" game with a super difficult intubation inside. This will allow us individually to be the airway super-hero that we dream we could be. But we don’t have super powers. None of us do. We do have some information though and information is power. NAP-4 out of the UK was the product of information collected by the College of Anaesthetists in the UK. Before that was published Toby Fogg had already started collecting airway data at the Royal North Shore Hospital in Sydney, Australia and beyond. Toby spoke to Minh Le Cong on his PHARM podcast 5 years ago. This rather helped get the word out and he followed up with a post on Lifeinthefastlane. https://lifeinthefastlane.com/do-you-know-if-you-really-own-the-airway/ 5 years later we caught up with him to find out how it is all going. Toby is still collecting the data. Some people collect stamps, some collect beer glasses. Toby collects airway data. He's been at it for about 7 years now with the cooperation of a significant number of hospitals around the country. He has been able to see the changing trends in Australian airway management from the publication of the NAP-4 audit to emerging practices such as Delayed Sequence Intubation, Apnoeic Oxygenation and the increasing use of ketamine and rocuronium for RSI. He has also had to learn the intricacies of setting up a database for potentially sensitive information. In the background Luna Park was in full swing with music playing and rides running, which reflected the rollercoaster ride that Toby has undertaken. Sounds like a laugh. The Airway Registry - http://www.airwayregistry.org.au/airway-heros.html 
The Emergency Care Institute - https://www.aci.health.nsw.gov.au/networks/eci https://lifeinthefastlane.com/do-you-know-if-you-really-own-the-airway/ Musical inspiration today is the reggae classic “Give me Power” by Lee “Scratch” Perry & The Upsetters. (I don’t think Lee was thinking of airway data though.)

Dr. Carolyn Lam:               Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. I'm Dr. Carolyn Lam, associate editor from the National Heart Center and Duke National University of Singapore. What is the association between fetal congenital heart defects and maternal risk of hypertensive disorders of pregnancy? We will be discussing new data in this area in just a moment, following these summaries.                                                 The first paper describes the effect of long-term metformin and lifestyle measures on coronary artery calcium. This is a paper from Dr. Goldberg of George Washington University Biostatistics Center and colleagues of the Diabetes Prevention Program Research Group. The Diabetes Prevention Program and its outcome study is a long-term intervention study in subjects with prediabetes, which showed reduced diabetes risk with lifestyle and metformin compared to placebo.                                                 In the current study, the authors looked at subclinical atherosclerosis, which was assessed in 2,029 participants using coronary artery calcium measurements after 14 years of average follow-up. They found that men but not women with prediabetes treated with metformin for an average duration of 14 years had lower coronary calcium scores than their placebo counterparts. No difference in coronary calcium scores was observed in the group receiving a lifestyle intervention as compared to the placebo group.                                                 These findings provide the first evidence that metformin may protect against coronary atherosclerosis in men with prediabetes, although demonstration that metformin reduces cardiovascular disease events in these subjects is still needed before firm therapeutic implications of these findings can be made. The reason for an absence of an effect in women is unclear and deserves further study.                                                 The next study provides insights on the physiology of angina from invasive catheter laboratory measurements during exercise. Dr. Asrress of Royal North Shore Hospital in Sydney, Australia, and colleagues, studied 40 patients with exertional angina and coronary artery disease who underwent cardiac catheterization via radial axis and performed incremental exercise using a supine cycle ergometer. As they developed limiting angina, sublingual GTN was administered to half the patients and all patients continued to exercise for two minutes at the same workload. Throughout exercise, distal coronary pressure and flow velocity, and central aortic pressure were recorded using sensor wires.                                                 Using this novel invasive approach, the authors showed that administration of GTN ameliorated angina by reducing myocardial oxygen demand as well as increasing supply with a key component being the reversal of exercise-induced coronary lesion vasoconstriction. This was evidenced by the fact that there was a relationship between the diastolic velocity pressure gradient with significant increase in relative stenosis severity. In keeping with exercise-induced vasoconstriction of stenosed epicardial segments and dilation of normal segments, with trends towards reversal with GTN.                                                 Thus, this study describes the development of a paradigm where patients with coronary artery disease can exercise while simultaneously having coronary and central aortic hemodynamics measured invasively, and has shown that this provides a unique opportunity to study mechanisms underlying the physiology of angina. In treating patients with exercise-induced angina, the results highlight the importance of after-load reduction and the use of agents that reduce arterial wave reflection and promote coronary artery vasodilation.                                                 The next study provides mechanistic insights into reverse cholesterol transport, where excess cholesterol is removed from macrophage-derived foam cells in atherosclerotic plaques. It suggests that melanocortin receptor-1, or MC1-R, may play a role. As background, the melanocortin system, consisting of melanocyte-stimulating hormones and their receptors, regulate a variety of physiological functions, ranging from skin pigmentation to centrally-mediated energy balance control. At the cellular level, the biological actions are mediated by G protein-coupled melanocortin receptors, such as MC1-R. MC1-R not only affects melanogenesis in the skin but also has immunomodulatory effects through its wide expression in the cells of the immune system.                                                 In the current study from Dr. Rinne of University of Turku in Finland, and colleagues, human and mouse atherosclerotic samples and primary mouse macrophages were used to study the regulatory functions of MC1-R. The impact of pharmacological MC1-R activation on atherosclerosis was further assessed in apolipoprotein E deficient mice. Their findings identified a novel role for MC1-R in macrophage cholesterol transport. Activation of MC1-R conferred protection against macrophage foam cell formation through a dual mechanism. It prevented cholesterol uptake while it concomitantly promoted reverse cholesterol transport by increasing the expression of ATP-binding cassette transporters, ABCA1 and ABCG1.                                                 Thus, the identification of MC1-R in lesional macrophages, demonstration of its role in regulating reverse cholesterol transport, combined with its established anti-inflammatory effects, suggests that MC1-R could be a novel new therapeutic target for preventing atherosclerosis.                                                 The next study suggests that obesity-related heart failure with preserved ejection fraction, or HFpEF, is a genuine form of cardiac failure and a clinically relevant phenotype that may require specific treatments. First author, Dr. Obokata, corresponding author, Dr. Borlaug, and colleagues from Mayo Clinic Rochester and Minnesota studied 99 patients with obese HFpEF with a BMI above 35, with 96 non-obese HFpEF with a BMI less than 30, and 71 non-obese controls without heart failure. All subjects underwent detailed clinical assessment, echocardiography, and invasive hemodynamic exercise testing.                                                 The authors found that, compared to non-obese HFpEF, obese HFpEF patients displayed greater volume overload, more biventricular remodeling, greater right ventricular dysfunction, worse exercise capacity, more impaired pulmonary vasodilation, and more profound hemodynamic arrangements, despite a lower NT-proBNP level. Obese HFpEF patients displayed other important contributors to high left ventricular filling pressures, including greater dependence on plasma volume expansion, increased pericardial restraint, and enhanced ventricular interaction, which was exaggerated as pulmonary pressure load increased.                                                 These data provide compelling evidence that patients with the obese HFpEF phenotype have real heart failure and display several pathophysiological mechanisms that differ from non-obese patients with HFpEF. These and other issues are discussed in an accompanying editorial by Dr. Dalane Kitzman and myself. We hope you enjoy it.                                                 The final study identifies a novel long noncoding RNA that regulates angiogenesis. As background, although we know that the mammalian genome is pervasively transcribed, a large proportion of the transcripts do not encode a protein, and are thus regarded as noncoding RNAs. Based on their length, they can be divided into small or long noncoding RNAs, long being described as more than 200 nucleotides. Although their function is not fully understood, long noncoding RNAs have been increasingly reported to mediate the expression of other genes, affect the organization of the nucleus, and modify other RNAs.                                                 In the current study by first author, Dr. Leisegang, corresponding author, Dr. Brandes, and colleagues of Goethe University in Frankfurt, Germany, epigenetically controlled long noncoding RNAs in human umbilical vein endothelial cells were searched by axon array analysis following knockdown of the histone demethylase JARID1B. The authors discovered a novel noncoding RNA named MANTIS to be strongly upregulated. MANTIS is located in the antisense strand of an intronic region of the gene for annexin A4, calcium- and phospholipid-binding protein. MANTIS is a nuclear long noncoding RNA that is enriched in endothelial cells but also expressed in other cell types. Reducing MANTIS levels led to impaired endothelial sprouting, tube formation, attenuated endothelial migration, and inhibition of the alignment of endothelial cells in response to shear stress.                                                 Brahma-like gene 1, or BRG-1, was identified as a direct interaction partner of MANTIS, implying a role of MANTIS in the formation of the switch/sucrose non-fermentable chromatin remodeling complex. MANTIS binding to BRG-1 was shown to stabilize the BRG-1 interaction, hence by inducing an open chromatin conformation, MANTIS was proposed to maintain the endothelial angiogenic potential. The implications of these findings are discussed in an accompanying editorial by Dr. Zampetaki and Mayr from Kings College London.                                                 That brings us to the end of our summaries. Now for our feature discussion.                                                 Today, we are going to be discussing the association between fetal congenital heart defects and maternal risk of hypertensive disorders of pregnancy. To discuss this, I have the first and corresponding author of our feature paper, Dr. Heather Boyd, from Statens Serum Institut in Copenhagen, and our familiar Dr. Sharon Reimold, content editor for special populations from UT Southwestern. Welcome, Heather and Sharon. Dr. Heather Boyd:            Thank you. Dr. Sharon Reimold:        Thank you. Dr. Carolyn Lam:               Heather, it's a topic that I can't say I'm very familiar with, association between fetal congenital heart defects and maternal risk of hypertensive disorders of pregnancy. Could you start by sharing why would we think there would be a link? What was the hypothesis you were testing? Dr. Heather Boyd:            A couple years ago, there was a paper published in the European Heart Journal that reported evidence of angiogenic imbalance in women with fetuses with major congenital heart defects, so women who were pregnant with babies that had heart defects, and then in fetuses that were terminated because of this kind of defect. My research group focuses a lot of attention on preeclampsia. In the last decade or so, angiogenic imbalance in preeclampsia has been a really hot topic. Women with preeclampsia, particularly women with early-onset preeclampsia, have big angiogenic imbalances. When we saw the European Heart Journal paper, we immediately thought, "What's the connection between preeclampsia and heart defects in the offspring?" Dr. Carolyn Lam:               Oh! Dr. Heather Boyd:            Exactly. That was our entry point to it, was the term "angiogenic imbalance" in that paper sort of was a flag for us. It wasn't a completely new idea, but we in Denmark have one big advantage when considering research questions that involve either rare exposures and/or rare outcomes, and that's our National Health Registry. We have the ability to assemble these huge cohorts and study conditions like heart defects with good power, so we decided just to go for it. Dr. Carolyn Lam:               That makes a lot of sense now. Please, tell us what you did and what you found. Dr. Heather Boyd:            The first thing we did was look at the association between carrying a baby with a heart defect and then whether the mom had preeclampsia later in the same pregnancy. We had information on almost 2 million pregnancies for this part of the study. We found that women carrying a baby with a heart defect were seven times as likely as women with structurally normal babies to develop early preterm preeclampsia. We defined that as preeclampsia where the baby has to be delivered before 34 weeks, so the really severe form of preeclampsia. Then, women carrying a baby with a heart defect were almost three times as likely to develop late preterm preeclampsia as well. That's where they managed to carry it until 34 weeks but it has to be delivered some time before 37 weeks.                                                 These findings were similar to those of other studies, but we were able to go a step further and look at individual heart defect subtypes. What we found there waws that these strong associations were similar across defect categories. Then we decided to see if we could shed any light on the origin of the problem, whether it was coming from the mom's side or the baby's side. To do this, we looked at women with at least two pregnancies in our study period to see whether preeclampsia in one pregnancy had any bearing on the chance of having a baby with a heart defect in another pregnancy or vice versa.                                                 This part of the study included 700,000 women. We found very similar findings. We found that women with early preterm preeclampsia in one pregnancy had eight times the risk of having a baby with a heart defect in a subsequent pregnancy. Late-term preeclampsia in one pregnancy was associated with almost three times the risk of offspring heart defects in later pregnancies. Then, we found that it worked the other way around too. Women who had a baby with a heart defect were twice as likely to have preterm preeclampsia in subsequent pregnancies.                                                 Those results were really, really exciting, because whatever mechanisms underlie the associations between preterm preeclampsia in moms and heart defects in the babies, they operate across pregnancies. Therefore, that pointed towards something maternal in origin. Dr. Carolyn Lam:               That is so fascinating. Sharon, please, share some of the thoughts, your own as well as those of the editors when we saw this paper. Dr. Sharon Reimold:        I think that there's a growing data about the links between hypertensive disorders of pregnancy and preeclampsia with subsequent abnormal maternal outcome. But this paper, I think, has implications for how we look at moms who are going to have offspring with congenital heart defects as well as those with preeclampsia. For instance, I would look at a patient now that has preeclampsia, especially in more than one pregnancy, to identify that they may be at risk to have offspring with congenital defects in the future if they have additional children. But the mom is also at risk based on other data for developing other cardiovascular risk factors and disease as she gets older. It was really the link going back and forth with the hypertensive disorders and the congenital defects that we found the most interesting. Dr. Carolyn Lam:               That struck me too, especially when you can look at multiple pregnancies and outcomes. That's amazing. You know what, Heather, could you share a little bit about what it's like working with these huge Danish databases? I think there must be a lot more than meets the eye. Dr. Heather Boyd:            It's an interesting question, because I'm a Canadian and I was trained in the US. I did my PhD in epidemiology at Emery, and then I moved to Copenhagen. When I first got here, I was absolutely floored at the possibility of doing studies with millions of women in them. It opens some amazing possibilities, like I said earlier, for certain outcomes and certain exposures. You just need to have a question where the information you want is registered. Dr. Carolyn Lam:               Yeah. But I think what I also want to put across is, having worked with big databases, and certainly not as big as that one, it's actually a lot of work. People might think, "Oh, it's just all sitting there." But, for example, how long did it take you to come to these observations and conclusions? Dr. Heather Boyd:            I have a fabulous statistician. I think she's the second author there, Saima Basit. She spends a lot of her time pulling together data from different registers. But yes, you're right. The data don't always just mesh nicely. The statisticians we have working with us are real pros at this sort of data slinging. Dr. Carolyn Lam:               Could I just pose one last question to both of you. What do you think are the remaining gaps? Dr. Sharon Reimold:        I think that this is a clinical link. Then, going back to figure more about what's going on biologically to set up this difference? Because right now there's really no intervention that's going to make a difference, it's just a risk going forward. This is sort of like medicine done backwards, that there's this association and now we need to figure out exactly why. Dr. Heather Boyd:            I can piggyback on what Sharon said a little bit, because I think one of the things we need to remember is that not all women with preeclampsia have babies with heart defects. Not by a long shot. What we need to do now is to figure out what distinguishes the women who do get this double whammy from the vast majority who don't.                                                 One of the things that Denmark does really nicely is that there are large bio banks. One of the things we want to do is go back to bank first trimester maternal blood samples and see if we can identify biomarkers that are unique to the women with both preterm preeclampsia and babies with heart defects. That's one of the things we're thinking about to address this gap. Because, as Sharon says, we've got to figure out what the mechanism is.                                                 The other thing we want to do is to see whether the association between preeclampsia and heart defects extends, for example, to other things, to cardiac functional deficits, for example, because it's probably not just severe structural defects. If there's an association, it's probably on a continuum. Are babies born to preeclamptic moms, do their cardiac outputs differ? Do their electrical parameters differ? Do they just have different hearts?                                                 We're really lucky because right now the Copenhagen Baby Heart Study is offering to scan the hearts of all infants born at one of the three major university hospitals in the Copenhagen area. We're about to have echocardiography data on 30,000 newborn hearts to help us look at this. I'm really excited about that possibility. Dr. Carolyn Lam:               I've learnt so much from this conversation. I'm sure the listeners will agree with me. Thank you both very, very much.

Dr Lisa Friederich recently joined Silkwood Medical with many years of experience as both a facial and body plastic surgeon under her belt. She has worked in adult and paediatric plastic surgery in Perth as well as at the plastic surgery unit at Royal Melbourne Hospital for 6 months before a final move to Sydney, where she completed her training in plastic surgery at Royal North Shore Hospital. Before her medical career, Dr Lisa Friederich studied Art and Photography where she learned to appreciate the finer details and a great understanding of aesthetics - it's those qualities that attracted her to the field of plastic surgery. Dr Friederich still enjoys photography in her free time, especially when it involves cityscapes or her "furry babies", her two dogs. There is nothing that makes Dr Friederich happier than spending the night in with her daughter and dogs, a good glass of wine, and a thrilling science fiction movie - she isn't afraid to admit she's a bit of a geek. Besides photography, sailing is a hobby Dr Friederich enjoys a lot. In fact, she is currently in the middle of a sailing course and can't wait to get her license and sail somewhere on her next holiday. While Dr Friederich likes all aspects of plastic surgery, she is particularly interested in gender reassignment surgery and has performed breast surgery on male and female patients as part of their gender reassignment journey. You can connect with Lisa at http://www.silkwoodmedical.com.au/meet-dr-lisa-friederich/

Infectious bacteria are becoming resistant to the drugs that used to kill them. The last new class of antibiotics was discovered in the 1980s. There is little in the development pipelines of the world's pharmaceutical industry. Drug companies got out of antibiotics as their attention switched to much more lucrative daily medicines for chronic diseases. Public funding on antibiotic research has also withered. Now that the gathering crisis of antibiotic resistance is becoming recognised by politicians, what are the options? Roland Pease explores how business, academia and governments might work together to avert a return to the medical dark ages.Image Credit: Hospital scientist inspects an unidentified culture in the Microbiology Department of Sydney's Royal North Shore Hospital, Greg Wood/AFP/Getty Images

The discovery and harnessing of antibiotic drugs in the mid-20th Century led some medics to predict the end of infectious diseases. But the bacteria fought and continue to fight back, evolving resistance to many of the drugs that used to kill them. Public health officials warn that without new drugs, medicine will return to the days where ‘a cut finger on Monday leads to death of Friday'. Without protective antibiotics to keep infections at bay, scores of standard surgical operations and chemotherapy for cancer will become too risky.Roland Pease looks at scientific issues behind the gathering crisis. The last new class of antibiotics was discovered in the 1980s. Are there any others in the pipeline?Image Credit: Hospital scientist inspects an unidentified culture in the Microbiology Department of Sydney's Royal North Shore Hospital, Greg Wood/AFP/Getty Images

Once the potential of Emu Oil in treating arthritis became known, experimentation began in earnest. Initial Australian government laboratory tests credited the oil with "creating a type of anti-inflammatory agent." Reports like this caused a media frenzy. After seeing the results, one popular Australian newspaper proclaimed "Emu Oil Beats Arthritis". The man primarily responsible for the change in Emu Oil's status from folk cure to medical wonder discovery is Dr. Peter Ghosh, director of the research lab at Sydney's Royal North Shore Hospital. For years, Dr. Ghosh has been one of Australia's leading authorities on arthritis, and has been engaged in arthritis research since the 1960's, often in conjunction with Dr. Michael Shitehouse. These two scientists are the continent's leading experts on the evaluation and development of new anti-arthritis treatments. Emu Oil Naturally Contains: * Vitamin E, a major antioxidant and healing agent * Vitamin A, a known skin repairer and antioxidant * Linoleic acid, which eases muscle aches and joint pain * Oleic acid, a proven skin cell regenerator, anti-wrinkle agent * Sapogens, proven skin softeners * Terpines, known antiseptics To learn more about Emu Oil . Each week Martin Pytela and Scott Paton discuss Holistic principles for healthy living. Life Enthusiast Co-op is built on over 25 years in study, health consultations and market research in the field of holistic and alternative medicine. We deliver solid time tested expertise. We are in this business not for the money, but for the passion, we have for sharing with others what we had to learn the hard way, through experience. We focus on high quality, innovative holistic solutions. Length: 27:34 Go to iTunes and review our podcast: iTunes Life Enthusiast Reviews and 5 star ratings If You Enjoyed This, Please Go To "FANS OF THIS SHOW" On The RIGHT And Then Click On "BECOME A FAN". In Addition, PLEASE CLICK On The “SEND TO A FRIEND” At The Bottom Of This Podcast…. COPY THE DATA And SEND THIS, and “My Pod Home Page URL”, To EVERYONE In Your ADDRESS BOOK…. FRIENDS Or ENEMIES! WANT TO BE NOTIFIED OF NEW EPISODES? ~~~~~~~~~~~~~~~~~~~~ Go To “Join my mailing list ” On The RIGHT………. When It Comes Up You Will See On This Page “Add me to Life Enthusiast''s mailing list:” ………. And Then type in your name and email address ………. Now Just Click “Save”. Technorati Tags: weight loss, Diet, Obesity, Dieting, Healthy Living,Food, Exercise, Fitness, Nutrition, Supplements, Lose Weight, Martin Pytela, Scott Paton.

Simon Finfer, MD, MBBS, MRCP, is one of the prominent keynote speakers set to present during the 36th Critical Care Congress February 17 to 21, 2007. He discusses his keynote presentation "The Clinical Role of Albumin in the Critically Ill" as well as his latest critical care endeavors. Dr. Fifner is a senior staff specialist in intensive care at Royal North Shore Hospital of Sydney. Dr Finfer received his training from London University and Westminster Medical School, London University. He also trained in pediatric intensive care at the world-renowned Hospital for Sick Children in Toronto, Canada.